Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.56 |
| ▸ | NOS1 | P29475 | 1/20 | 0.56 |
| ▸ | NOS2 | P35228 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.39 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.39 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL56649 | 0.83 | NOS3 (0.52) | NOS3NOS1NOS2NPC1RAB9A | |
| SCHEMBL6770614 | 0.83 | NOS3 (0.47) | NOS3NOS1NOS2NPC1RAB9A | |
| SCHEMBL4758381 | 0.82 | TRPA1 (0.54) | NOS3NOS1NOS2NPC1RAB9A | |
| SCHEMBL11036926 | 0.81 | NOS3 (0.41) | NOS3NOS1NOS2NPC1RAB9A | |
| SCHEMBL7978788 | 0.81 | DRD1 (0.42) | NOS3NOS1NOS2 | |
| SCHEMBL519052 | 0.74 | CYP2A6 (0.45) | NOS3NOS1NOS2NPC1RAB9A | |
| SCHEMBL2313991 | 0.74 | NOS3 (0.48) | NOS3NOS1NOS2NPC1RAB9A | |
| SCHEMBL5958858 | 0.74 | NOS3 (0.59) | NOS3NOS1NOS2NPC1RAB9A | |
| SCHEMBL4199895 | 0.74 | NOS3 (0.59) | NOS3NOS1NOS2NPC1RAB9A | |
| SCHEMBL29351986 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 939 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150141410-A1 | GPR17 Receptor Modulators | UNIVERSITA' DEGLI STUDI DI MILANO (IT) | 2015-05-21 | — | — | US | claimed |
| US-20090214444-A1 | POLY AROMATIC SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2009-08-27 | — | — | US | claimed |
| US-20080007158-A1 | Linear Polysiloxanes, Silicone Composition, and Organic Light-Emitting Diode | FAROOQ OMAR | 2008-01-10 | — | — | US | claimed |
| US-20060035884-A1 | N-cyclic sulfonamido inhibitors of gamma secretase | ELAN PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | US | claimed |
| US-20050288347-A1 | Certain triazole-based compounds, compositions, and uses thereof | AGRIUS GROUP, LLC. | 2005-12-29 | — | — | US | claimed |
| EP-1301187-B1 | PURINE-2,6-DIONES WHICH ARE INHIBITORS OF THE ENZYME DIPEPTIDYL PEPTIDASE IV (DPP-IV) | NOVO NORDISK AS (DK) | 2005-07-06 | — | — | EP | claimed |
| US-6235730-B1 | ANTICHOLESTEROL AGENT, ANTILIPEMIC AGENT | JAPAN TOBACCO, INC. (JP) | 2001-05-22 | — | — | US | claimed |
| EP-0519353-B1 | Indolizin derivatives, process for their preparation and pharmaceutical composition containing them | FUJISAWA PHARMACEUTICAL CO (JP) | 2000-08-16 | — | — | EP | claimed |
| EP-1019367-A1 | DERIVATIVES OF 2,5- AND 3,5-DISUBSTITUTED ANILINES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-07-19 | — | — | EP | claimed |
| US-6043247-A | A SUBSTITUTED ACRYLIC ACIDS FOR USE IN TREATMENT OF HUMAN AND ANIMAL DISORDERS, AND PURIFICATION OF PROTEINS OR GLYCOPROTEINS, AND TO THEIR USE IN DIAGNOSIS | NOVO NORDISK A/S (DK) | 2000-03-28 | — | — | US | claimed |
| EP-0970954-A1 | 3-PIPERIDYL-4-OXOQUINAZOLINE DERIVATIVES AND MEDICINCAL COMPOSITIONS CONTAINING THE SAME | JAPAN TOBACCO INC. (JP) | 2000-01-12 | — | — | EP | claimed |
| US-5925731-A | FOR TREATMENT OR PROPHYLAXIS OF ACUTE RENAL FAILURE, MYOCARDIAL INFARCTION, HEPATIC DISEASE, OR BRONCHIAL DISORDER | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-07-20 | — | — | US | claimed |
| WO-1999007672-A1 | DERIVATIVES OF 2,5- AND 3,5-DISUBSTITUTED ANILINES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1999-02-18 | — | — | WO | claimed |
| EP-0552489-B1 | Peptide, production and use thereof | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1998-03-04 | — | — | EP | claimed |
| EP-0458207-B1 | Indole derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-03-26 | — | — | EP | claimed |
| EP-0471236-B1 | Imidazopyridine derivatives and their use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1995-03-15 | — | — | EP | claimed |
| EP-0519353-A2 | Indolizin derivatives, process for their preparation and pharmaceutical composition containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-12-23 | — | — | EP | claimed |
| EP-0471236-A1 | Imidazopyridine derivatives and their use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-02-19 | — | — | EP | claimed |
| EP-0458207-A2 | Indole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-11-27 | — | — | EP | claimed |
| WO-2024151809-A1 | INHIBITORS OF BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE 2 (BMPR2) AND METHODS USING SAME | BAYLOR COLLEGE OF MEDICINE (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024145273-A2 | N-MYRISTOYLTRANSFERASE INHIBITORS AND METHODS OF USE | SEATTLE CHILDREN'S HOSPITAL (D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE) (US) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024145687-A1 | BIOREACTIVE PROTEINS CONTAINING AN UNNATURAL AMINO ACID AND ARGININE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-07-04 | — | — | WO | disclosed |
| EP-4392430-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | Yale University (US) | 2024-07-03 | — | — | EP | disclosed |
| US-20240200041-A1 | Modified Pyrococcus Polymerases and Uses Thereof | FIRST-CITIZENS BANK & TRUST COMPANY | 2024-06-20 | — | — | US | disclosed |
| EP-3377473-B1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2024-06-19 | — | — | EP | disclosed |
| EP-3538101-B1 | INHIBITORS OF CANCER AND/OR METASTASIS | UNIV VIRGINIA COMMONWEALTH (US) | 2024-06-19 | — | — | EP | disclosed |
| WO-2024124172-A1 | COMPOSITIONS AND METHODS FOR STIMULATING AND/OR ENHANCING EXERCISE MOTIVATION AND/OR PHYSICAL PERFORMANCE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2024-06-13 | — | — | WO | disclosed |
| US-20240182875-A1 | ENGINEERED PYROCOCCUS ENZYMES AND USES THEREOF | FIRST-CITIZENS BANK & TRUST COMPANY | 2024-06-06 | — | — | US | disclosed |
| US-20240181073-A1 | Antibody-Drug Conjugates Comprising an Anti-BCMA Antibody | VIVASOR, INC. | 2024-06-06 | — | — | US | disclosed |
| US-20240181067-A1 | TARGETED BIFUNCTIONAL DEGRADERS AND METHODS USING SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-06 | — | — | US | disclosed |
| US-20240181438-A1 | UNSYMMETRICAL N-HETEROCYCLIC CARBENE CATALYSTS AND METHODS USING SAME | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2024-06-06 | — | — | US | disclosed |
| WO-2024112744-A1 | CATALYSTS AND METHODS OF USE THEREOF | YALE UNIVERSITY (US) | 2024-05-30 | — | — | WO | disclosed |
| US-20240174651-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2024-05-30 | — | — | US | disclosed |
| US-20240174709-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2024-05-30 | — | — | US | disclosed |
| US-20240174708-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | AMBAGON THERAPEUTICS INC (US) | 2024-05-30 | — | — | US | disclosed |
| EP-4373487-A1 | CORONAVIRUS MAIN PROTEASE INHIBITORS AND METHODS USING SAME | Baylor College of Medicine (US) | 2024-05-29 | — | — | EP | disclosed |
| US-11993592-B2 | Phebox ligands and methods of making same | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2024-05-28 | — | — | US | disclosed |
| US-20240167089-A1 | NANOARRAYS AND METHODS OF USE THEREOF | FIRST-CITIZENS BANK & TRUST COMPANY | 2024-05-23 | — | — | US | disclosed |
| US-20240165597-A1 | STERICALLY HINDERED N-ALIPHATIC N-HETEROCYCLIC CARBENE CATALYSTS AND METHODS USING SAME | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2024-05-23 | — | — | US | disclosed |
| EP-4371982-A2 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX Pharmaceuticals, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| US-11987554-B2 | Protease inhibitors as antivirals | VIVASOR, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-11987709-B2 | Silicon containing detectable compounds and uses thereof | Singular Genomics Systems, Inc. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20240158355-A1 | BET SUBFAMILY INHIBITORS AND METHODS USING SAME | BAYLOR COLLEGE MEDICINE (US) | 2024-05-16 | — | — | US | disclosed |
| WO-2024097160-A1 | TRANSITION METAL COMPLEXES FOR MRI APPLICATIONS AND METHODS OF USE | YALE UNIVERSITY (US) | 2024-05-10 | — | — | WO | disclosed |
| US-20240150338-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2024-05-09 | — | — | US | disclosed |
| US-20240148885-A1 | TARGETED BIFUNCTIONAL DEGRADERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-05-09 | — | — | US | disclosed |
| EP-4365180-A1 | RARE EARTH COMPLEX | Tosoh Corporation (JP) | 2024-05-08 | — | — | EP | disclosed |
| US-11974990-B2 | TXNIP-TRX complex inhibitors and methods of using the same | CITY OF HOPE (US) | 2024-05-07 | — | — | US | disclosed |
| US-11970735-B2 | Nucleotide cleavable linkers and uses thereof | Singular Genomics Systems, Inc. (US) | 2024-04-30 | — | — | US | disclosed |
| US-20240132887-A1 | PROTEIN ARGININE METHYLTRANSFERASE 9 INHIBITORS AND METHODS OF USE | CITY OF HOPE (US) | 2024-04-25 | — | — | US | disclosed |
| US-11964984-B2 | TXNIP-TRX complex inhibitors and methods of using the same | CITY OF HOPE (US) | 2024-04-23 | — | — | US | disclosed |
| US-20240124466-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-18 | — | — | US | disclosed |
| US-20240124645-A1 | COMPOSITION FOR REVERSIBLE POLYMERIZATION OF THIOESTER AND METHODS THEREOF | UNIV COLORADO REGENTS (US) | 2024-04-18 | — | — | US | disclosed |
| US-11958877-B2 | Nucleotide analogues | Singular Genomics Systems, Inc. (US) | 2024-04-16 | — | — | US | disclosed |
| WO-2024077232-A2 | COMPOSITIONS AND METHODS FOR T CELL TARGETED DELIVERY OF THERAPEUTIC AGENTS AND ACTIVATION OF T CELLS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2024-04-11 | — | — | WO | disclosed |
| EP-4347543-A2 | PROTEINS HAVING UNNATURAL AMINO ACIDS AND METHODS OF USE | The Regents of the University of California (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4347559-A1 | FLUORINATED TRYPTAMINE COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | Saint Joseph's University (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4347034-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACEA Therapeutics, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20240101979-A1 | MODIFIED ARCHAEAL FAMILY B POLYMERASES | FIRST-CITIZENS BANK & TRUST COMPANY | 2024-03-28 | — | — | US | disclosed |
| EP-3583096-B1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2024-03-27 | — | — | EP | disclosed |
| US-20240092759-A1 | Non-Covalent Inhibitors of the Main Protease of SARS-CoV-2 and Methods of Use | UNIV YALE (US) | 2024-03-21 | — | — | US | disclosed |
| US-11932789-B2 | Luminescent compound | TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-03-19 | — | — | US | disclosed |
| WO-2024050352-A2 | Branched Lipid Compositions, Lipid Nanoparticles (LNPs) Comprising the Same, and Methods of Use Thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2024-03-07 | — | — | WO | disclosed |
| EP-4330214-A2 | BIOREACTIVE PROTEINS CONTAINING UNNATURAL AMINO ACIDS | The Regents of the University of California (US) | 2024-03-06 | — | — | EP | disclosed |
| US-11918582-B2 | Pyrazole pyrimidine compounds and uses thereof | RAPT THERAPEUTICS, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| WO-2024044771-A2 | PEGYLATION OF CAR T CELL THERAPEUTICS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044741-A2 | EFFICIENT METHOD FOR MAKING HIGHLY PURIFIED 5'-CAPPED OLIGONUCLEOTIDES | TRILINK BIOTECHNOLOGIES, LLC (US) | 2024-02-29 | — | — | WO | disclosed |
| US-11905267-B2 | High triplet yield phenothiazine donor-acceptor complexes for photoredox catalysis | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2024-02-20 | — | — | US | disclosed |
| US-20240041768-A1 | MULTIFUNCTIONAL pO2/pH-SENSITIVE THERANOSTIC LIPOSOME NANOCARRIERS AND METHODS OF USING SAME | UNIV YALE (US) | 2024-02-08 | — | — | US | disclosed |
| US-11891399-B2 | Inhibitors of cancer invasion, attachment, and/or metastasis | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2024-02-06 | — | — | US | disclosed |
| US-11891633-B2 | Modified pyrococcus polymerases and uses thereof | Singular Genomics Systems, Inc. (US) | 2024-02-06 | — | — | US | disclosed |
| WO-2024026410-A2 | NEUROTROPHIC RECEPTOR TYROSINE KINASE (NTRK) INHIBITORS AND METHODS USING SAME | BAYLOR COLLEGE OF MEDICINE (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024025845-A1 | FOLATE-CONJUGATED DRUGS AND USES THEREOF | SORRENTO THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| US-11884943-B2 | Engineered Pyrococcus enzymes and uses thereof | Singular Genomics Systems, Inc. (US) | 2024-01-30 | — | — | US | disclosed |
| US-11878993-B2 | Nucleotide analogues | Singular Genomics Systems, Inc. (US) | 2024-01-23 | — | — | US | disclosed |
| WO-2024015761-A2 | GΑLPHA12 INHIBITORS AND METHODS USING SAME | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2024015617-A2 | METHODS OF MAKING AN ALKENE FROM A POLYMER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-18 | — | — | WO | disclosed |
| US-20240009169-A9 | PPARG Modulators for the Treatment of Osteoporosis | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2024-01-11 | — | — | US | disclosed |
| WO-2024010585-A1 | NON-COVALENT INHIBITORS OF THE MAIN PROTEASE OF SARS-COV-2 AND METHODS OF USE | YALE UNIVERSITY (US) | 2024-01-11 | — | — | WO | disclosed |
| EP-4301767-A1 | BIOREACTIVE COMPOUNDS AND METHODS OF USE THEREOF | The Regents of the University of California (US) | 2024-01-10 | — | — | EP | disclosed |
| US-11858879-B2 | PARG inhibitors and method of use thereof | CITY OF HOPE (US) | 2024-01-02 | — | — | US | disclosed |
| EP-4294384-A1 | TARGETED BIFUNCTIONAL DEGRADERS | Yale University (US) | 2023-12-27 | — | — | EP | disclosed |
| US-11851687-B2 | Modified Pyrococcus polymerases and uses thereof | Singular Genomics Systems, Inc. (US) | 2023-12-26 | — | — | US | disclosed |
| US-11845923-B2 | Modified Archaeal family B polymerases | Singular Genomics Systems, Inc. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20230399692-A1 | NUCLEIC ACID DELIVERY SCAFFOLDS | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-12-14 | — | — | US | disclosed |
| WO-2023239790-A2 | ENHANCING DENTIN BONDING DURABILITY USING QUATERNARY PYRIDINIUM SALTS | ADA Science and Research Institute LLC (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230399303-A1 | Macrophage Migration Inhibitory Factor Inhibitors, and Methods of Making and Using Same | UNIV YALE (US) | 2023-12-14 | — | — | US | disclosed |
| EP-4284372-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | University of Florida Research Foundation, Incorporated (US) | 2023-12-06 | — | — | EP | disclosed |
| WO-2023225097-A1 | PYRIMIDOPYRIMIDONE COMPOUNDS AND METHODS OF USE THEREOF | SOLTEGO, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023220734-A2 | BISPHOSPHONATE LIPIDS, LIPID NANOPARTICLE COMPOSITIONS COMPRISING THE SAME, AND METHODS OF USE THEREOF FOR TARGETED DELIVERY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20230365542-A1 | Selective Agonists of 5-HT2A Receptor and Methods of Use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-11-16 | — | — | US | disclosed |
| WO-2023215796-A2 | SILOXANE-BASED LIPIDS, LIPID NANOPARTICLE COMPOSITIONS COMPRISING THE SAME, AND METHODS OF USE THEREOF FOR TARGETED DELIVERY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-11-09 | — | — | WO | disclosed |
| US-20230346943-A1 | SPACER-MEDIATED CONTROL OF UNCAGING PHOTOCAGED MOLECULES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-11-02 | — | — | US | disclosed |
| US-20230346951-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | YALE UNIVERSITY | 2023-11-02 | — | — | US | disclosed |
| EP-4262792-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | The Scripps Research Institute (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-4263868-A1 | NANOARRAYS AND METHODS OF USE THEREOF | Singular Genomics Systems, Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| US-11795505-B2 | Nucleic acid delivery scaffolds | Singular Genomics Systems, Inc. (US) | 2023-10-24 | — | — | US | disclosed |
| WO-2023201301-A2 | BIODEGRADABLE LIPIDOIDS AND COMPOSITIONS AND METHODS OF USE THEREOF FOR TARGETED DELIVERY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-10-19 | — | — | WO | disclosed |
| US-20230331670-A1 | GLYCEROL COMPOUNDS AND METHODS OF USE | ENZYCHEM LIFESCIENCES CORP (KR) | 2023-10-19 | — | — | US | disclosed |
| EP-4259118-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | The Scripps Research Institute (US) | 2023-10-18 | — | — | EP | disclosed |
| US-20230322715-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-10-12 | — | — | US | disclosed |
| US-20230322668-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACEA Therapeutics, Inc. (US) | 2023-10-12 | — | — | US | disclosed |
| WO-2023196432-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230322741-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-11779665-B2 | Electrochemical flash fluorination and radiofluorination | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-10 | — | — | US | disclosed |
| WO-2023178204-A1 | ENGINEERED ANTIBODIES AS MOLECULAR DEGRADERS THROUGH CELLULAR RECEPTORS | YALE UNIVERSITY (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023178199-A2 | TARGETED BIFUNCTIONAL DEGRADERS | YALE UNIVERSITY (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230295437-A1 | SILICON CONTAINING DETECTABLE COMPOUNDS | Singular Genomics Systems, Inc. | 2023-09-21 | — | — | US | disclosed |
| WO-2023178202-A2 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | YALE UNIVERSITY (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023173026-A1 | ANTIBODY-DRUG CONJUGATES AND USES THEREOF | SORRENTO THERAPEUTICS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023172667-A2 | SUBSTITUTED IMIDAZO[1,5-a]PYRIDINE N-HETEROCYCLIC CARBENE (NHC) LIGANDS, CATALYST COMPLEXES THEREOF, AND METHODS USING SAME | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023172665-A2 | NUCLEIC ACID DELIVERY SCAFFOLDS | Singular Genomics Systems, Inc. (US) | 2023-09-14 | — | — | WO | disclosed |
| US-20230287204-A1 | OXIDIZED POLYISOBUTENE COMPOUNDS AND METHODS OF MAKING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-09-14 | — | — | US | disclosed |
| US-11753373-B2 | Protease inhibitors as antivirals | ACEA Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230272202-A1 | OXIDIZED POLYETHYLENE COMPOUNDS AND METHODS OF MAKING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-08-31 | — | — | US | disclosed |
| WO-2023164544-A2 | NOVEL IONIZABLE CATIONIC LIPIDS | SORRENTO THERAPEUTICS, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| US-20230271994-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | UNIV YALE (US) | 2023-08-31 | — | — | US | disclosed |
| EP-4232027-A1 | MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS, AND METHODS OF MAKING AND USING SAME | Yale University (US) | 2023-08-30 | — | — | EP | disclosed |
| US-11739121-B2 | EPHA2 agonists and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230265099-A1 | SIK INHIBITORS AND METHODS OF USE THEREOF | SOLTEGO, INC. (US) | 2023-08-24 | — | — | US | disclosed |
| US-20230257414-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-08-17 | — | — | US | disclosed |
| WO-2023152709-A1 | RNA POLYMERASE INHIBITORS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-08-17 | — | — | WO | disclosed |
| EP-3377474-B1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2023141648-A1 | 2-FLUOROETHYL PROCARBAZINE COMPOUNDS | YALE UNIVERSITY (US) | 2023-07-27 | — | — | WO | disclosed |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | UNIV YALE (US) | 2023-07-27 | — | — | US | disclosed |
| EP-4214196-A1 | GLYCEROL COMPOUNDS AND METHODS OF USE | Enzychem Lifesciences Corporation (KR) | 2023-07-26 | — | — | EP | disclosed |
| US-20230227798-A1 | MODIFIED THERMOCCOCUS POLYMERASES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-07-20 | — | — | US | disclosed |
| US-20230221637-A1 | Holographic Recording Materials and Methods of Making Same | UNIV COLORADO REGENTS (US) | 2023-07-13 | — | — | US | disclosed |
| US-11697736-B2 | Silicon containing detectable compounds | Singular Genomics Systems, Inc. (US) | 2023-07-11 | — | — | US | disclosed |
| US-20230212202-A1 | TREATMENT OF MGMT DEFICIENT CANCER WITH 2-FLUOROETHYL-SUBSTITUTED NITROSOUREAS AND OTHER COMPOUNDS | YALE UNIVERSITY | 2023-07-06 | — | — | US | disclosed |
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-06-29 | — | — | US | disclosed |
| WO-2023122078-A1 | HETEROBIDENTATE IMIDAZO[1,5-A]PYRIDINE AND IMIDAZO[1,5-A]QUINOLINE N-HETEROCYCLIC CARBENE (NHC) LIGANDS, CATALYST COMPLEXES THEREOF, AND METHODS USING SAME | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20230203003-A1 | Notch Inhibitors and Uses Thereof | STEMSYNERGY THERAPEUTICS, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230202974-A1 | CASPASE 6 INHIBITORS AND USES THEREOF | UNIV CALIFORNIA (US) | 2023-06-29 | — | — | US | disclosed |
| WO-2023107920-A1 | ANISAMIDE-CONTAINING LIPIDS AND COMPOSITIONS AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20230181607-A1 | THIOSACCHARIDES FOR USE IN TREATING CORONAVIRUS INFECTION | The University of the Regents of California (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183215-A1 | Notch Inhibitors and Uses Thereof | STEMSYNERGY THERAPEUTICS, INC. | 2023-06-15 | — | — | US | disclosed |
| US-20230174690-A1 | COMPOSITIONS AND METHODS FOR SINGLE-STEP MULTIPURPOSE SURFACE FUNCTIONALIZATION | UNIV RUTGERS (US) | 2023-06-08 | — | — | US | disclosed |
| WO-2023097251-A1 | OLIGONUCLEOTIDE-CONTAINING TRANSCRIPTION FACTOR TARGETING CHIMERAS | YALE UNIVERSITY (US) | 2023-06-01 | — | — | WO | disclosed |
| US-20230158150-A1 | COMPOUND COMPRISING A NUCLEIC ACID AND A HALF-LIFE EXTENSION MOTIF | NOVARTIS AG (CH) | 2023-05-25 | — | — | US | disclosed |
| US-20230159678-A1 | METHODS OF POLYMERIZATION WITH AROMATIC THIOL INITIATORS | NATIONAL SCIENCE FOUNDATION | 2023-05-25 | — | — | US | disclosed |
| US-20230160001-A1 | NUCLEOTIDE CLEAVABLE LINKERS WITH RIGID SPACERS AND USES THEREOF | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-05-25 | — | — | US | disclosed |
| WO-2023091985-A1 | COMPOUNDS TARGETING PMP22 FOR THE TREATMENT OF CHARCOT-MARIE-TOOTH DISEASE | DTX PHARMA, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| US-20230150960-A1 | COMPOSITIONS AND METHODS OF USING CYANINE DYES TO TARGET CANCER AND MITOCHONDRIA | UNIV JEFFERSON (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230150956-A1 | MYC INHIBITORS AND USES THEREOF | STEMSYNERGY THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230148299-A1 | FEM1B PROTEIN BINDING AGENTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-05-11 | — | — | US | disclosed |
| US-20230142739-A1 | PROTEIN-PROTEIN INTERACTION STABILIZERS | UNIV CALIFORNIA (US) | 2023-05-11 | — | — | US | disclosed |
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-09 | — | — | US | disclosed |
| US-20230133817-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230133667-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230132808-A1 | WNT/CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | CITY OF HOPE | 2023-05-04 | — | — | US | disclosed |
| US-20230135758-A1 | ELONGATION FACTOR 1-ALPHA INHIBITORS AND USES THEREOF | UNIV CALIFORNIA (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230117830-A1 | COMPLEXES OF N-HETEROCYCLIC CARBENES FOR TRANSITION METAL CATALYSIS | NATIONAL SCIENCE FOUNDATION | 2023-04-20 | — | — | US | disclosed |
| WO-2023064458-A1 | SELECTIVE JAK2 INHIBITORS AND METHODS OF USE | YALE UNIVERSITY (US) | 2023-04-20 | — | — | WO | disclosed |
| US-11629380-B2 | Nanoarrays and methods of use thereof | Singular Genomics Systems, Inc. (US) | 2023-04-18 | — | — | US | disclosed |
| US-20230111132-A1 | STABILIZATION OF MHC COMPLEXES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-04-13 | — | — | US | disclosed |
| US-20230103984-A1 | Lyotropic Gyroid Mesophase Compositions, Polymer Compositions Comprising the Same, Methods of Preparation Thereof, and Methods of Using the Same | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2023-04-06 | — | — | US | disclosed |
| US-20230108783-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | NOVARTIS AG (CH) | 2023-04-06 | — | — | US | disclosed |
| US-20230105381-A1 | COMPOSITIONS AND METHODS FOR BIOORTHOGONAL SURFACE COATING | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-04-06 | — | — | US | disclosed |
| WO-2023056418-A1 | LIPID NANOPARTICLE (LNP) COMPOSITIONS AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-04-06 | — | — | WO | disclosed |
| US-20230101281-A1 | SILICON CONTAINING DETECTABLE COMPOUNDS AND USES THEREOF | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-03-30 | — | — | US | disclosed |
| WO-2023049716-A1 | COMPOUNDS TARGETING NRL FOR THE TREATMENT OF RETINITIS PIGMENTOSA | DTX PHARMA, INC. (US) | 2023-03-30 | — | — | WO | disclosed |
| US-20230100472-A1 | High Triplet Yield Phenothiazine Donor-Acceptor Complexes For Photoredox Catalysis | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2023-03-30 | — | — | US | disclosed |
| US-20230096016-A1 | NETWORK TOUGHENING OF ADDITIVELY MANUFACTURED, HIGH GLASS TRANSITION TEMPERATURE MATERIALS VIA SEQUENTIALLY CURED, INTERPENETRATING POLYMERS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2023-03-30 | — | — | US | disclosed |
| US-20230096500-A1 | LIGANDS FOR TRANSITION METAL CATALYSTS | NATIONAL SCIENCE FOUNDATION | 2023-03-30 | — | — | US | disclosed |
| US-20230095750-A1 | FLOW CHEMISTRY SYNTHESIS OF ISOCYANATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-03-30 | — | — | US | disclosed |
| US-11613544-B2 | Substituted imidazo[1,5-a]pyrazines for modulation of IRE1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-28 | — | — | US | disclosed |
| US-20230087994-A1 | TARGETED BIFUNCTIONAL DEGRADERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-03-23 | — | — | US | disclosed |
| US-20230091121-A1 | CALPAIN-2 INHIBITOR COMPOUNDS AND METHODS OF TREATMENT | UNITED STATES GOVERNMENT | 2023-03-23 | — | — | US | disclosed |
| US-20230090282-A1 | ENGINEERED ANTIBODIES AS MOLECULAR DEGRADERS THROUGH CELLULAR RECEPTORS | UNIV YALE (US) | 2023-03-23 | — | — | US | disclosed |
| US-20230083388-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | UNIV YALE (US) | 2023-03-16 | — | — | US | disclosed |
| US-20230072933-A1 | PPARG Modulators for the Treatment of Osteoporosis | SCRIPPS RESEARCH INST (US) | 2023-03-09 | — | — | US | disclosed |
| EP-4143256-A1 | OXIDIZED POLYISOBUTENE COMPOUNDS AND METHODS OF MAKING THE SAME | The Regents of The University of California (US) | 2023-03-08 | — | — | EP | disclosed |
| EP-4142934-A1 | OXIDIZED POLYETHYLENE COMPOUNDS AND METHODS OF MAKING THE SAME | The Regents of The University of California (US) | 2023-03-08 | — | — | EP | disclosed |
| US-11597727-B2 | Inhibitors of integrin alpha 2 beta 1 and methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-07 | — | — | US | disclosed |
| US-20230066830-A1 | METHODS AND COMPOSITIONS FOR INDUCING APOPTOSIS IN CANCER STEM CELLS | UNIV VIRGINIA COMMONWEALTH (US) | 2023-03-02 | — | — | US | disclosed |
| US-20230063768-A1 | IMMUNOPHILIN BINDING AGENTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-03-02 | — | — | US | disclosed |
| WO-2023028590-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | YALE UNIVERSITY (US) | 2023-03-02 | — | — | WO | disclosed |
| US-20230052740-A1 | MODULATORS OF CIRCADIAN RHYTHMS AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2023-02-16 | — | — | US | disclosed |
| US-20230052528-A1 | TASPASE1 INHIBITORS AND USES THEREOF | UNIV CALIFORNIA (US) | 2023-02-16 | — | — | US | disclosed |
| US-20230041523-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE AND METABOLIC DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2023-02-09 | — | — | US | disclosed |
| US-20230035796-A1 | CURCUMINOIDS, ANALOGS THEREOF, AND METHODS OF MAKING THE SAME | WISYS TECHNOLOGY FOUNDATION, INC. | 2023-02-02 | — | — | US | disclosed |
| US-20230029301-A1 | SCALEABLE PREPARATION OF POLYKETIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-01-26 | — | — | US | disclosed |
| US-20230022558-A1 | PHEBOX LIGANDS AND METHODS OF MAKING SAME | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2023-01-26 | — | — | US | disclosed |
| US-20230028359-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-01-26 | — | — | US | disclosed |
| US-20230026438-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACEA Therapeutics, Inc. | 2023-01-26 | — | — | US | disclosed |
| WO-2023004291-A1 | CORONAVIRUS MAIN PROTEASE INHIBITORS AND METHODS USING SAME | BAYLOR COLLEGE OF MEDICINE (US) | 2023-01-26 | — | — | WO | disclosed |
| US-11554178-B2 | Compositions and methods of modulating macrophage activity | CITY OF HOPE (US) | 2023-01-17 | — | — | US | disclosed |
| WO-2023282236-A1 | RARE EARTH COMPLEX | 東ソー株式会社 | 2023-01-12 | — | — | WO | disclosed |
| US-20230011240-A1 | MODIFIED ARCHAEAL FAMILY B POLYMERASES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-01-12 | — | — | US | disclosed |
| US-20230001027-A1 | METAL CHELATING AGENTS AND METHODS OF USING THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-01-05 | — | — | US | disclosed |
| US-20220411396-A1 | TRIOXOLANE AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-12-29 | — | — | US | disclosed |
| US-20220411366-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-29 | — | — | US | disclosed |
| US-11535754-B2 | Silicon containing detectable compounds and uses thereof | Singular Genomics Systems, Inc. (US) | 2022-12-27 | — | — | US | disclosed |
| WO-2022266210-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-12-22 | — | — | WO | disclosed |
| EP-4103188-A1 | MYC INHIBITORS AND USES THEREOF | StemSynergy Therapeutics, Inc. (US) | 2022-12-21 | — | — | EP | disclosed |
| US-11530205-B2 | GLP-1 receptor modulators | RECEPTOS LLC (US) | 2022-12-20 | — | — | US | disclosed |
| US-11530180-B2 | Alpha-5 beta-1 inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-12-20 | — | — | US | disclosed |
| US-20220396834-A1 | NANOARRAYS AND METHODS OF USE THEREOF | FIRST-CITIZENS BANK & TRUST COMPANY | 2022-12-15 | — | — | US | disclosed |
| EP-4100007-A1 | ELONGATION FACTOR 1-ALPHA INHIBITORS AND USES THEREOF | The Regents of the University of California (US) | 2022-12-14 | — | — | EP | disclosed |
| WO-2022256505-A2 | PROTEINS HAVING UNNATURAL AMINO ACIDS AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022256434-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACEA Therapeutics, Inc. (US) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022256554-A1 | FLUORINATED TRYPTAMINE COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | UNIVERSITY OF THE SCIENCES (US) | 2022-12-08 | — | — | WO | disclosed |
| US-20220388980-A1 | QUINOLINE INHIBITORS OF RAD52 AND METHODS OF USE | UNIV DREXEL (US) | 2022-12-08 | — | — | US | disclosed |
| EP-4097223-A1 | STRAD-BINDING AGENTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-12-07 | — | — | EP | disclosed |
| EP-3615524-B1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC (US) | 2022-11-09 | — | — | EP | disclosed |
| EP-4081254-A1 | STABILIZATION OF MHC COMPLEXES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-11-02 | — | — | EP | disclosed |
| US-20220339155-A1 | METTL16 INHIBITORS AND USES THEREOF | CITY OF HOPE | 2022-10-27 | — | — | US | disclosed |
| EP-4072541-A1 | ALPHA-5 BETA-1 INHIBITORS | The Regents of the University of California (US) | 2022-10-19 | — | — | EP | disclosed |
| WO-2022187311-A1 | STERICALLY HINDERED N-ALIPHATIC N-HETEROCYCLIC CARBENE CATALYSTS AND METHODS USING SAME | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2022-09-09 | — | — | WO | disclosed |
| WO-2022159454-A1 | BET SUBFAMILY INHIBITORS AND METHODS USING SAME | BAYLOR COLLEGE OF MEDICINE (US) | 2022-07-28 | — | — | WO | disclosed |
| US-20220202772-A1 | COMPOSITIONS AND METHODS FOR INHIBITING RIBOSOME INACTIVATING PROTEINS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2022-06-30 | — | — | US | disclosed |
| EP-4017857-A1 | METTL16 INHIBITORS AND USES THEREOF | City of Hope (US) | 2022-06-29 | — | — | EP | disclosed |
| WO-2022133303-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-06-23 | — | — | WO | disclosed |
| US-20220194971-A1 | SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | RECEPTOS LLC | 2022-06-23 | — | — | US | disclosed |
| US-20220194888-A1 | ANTI-BACTERIAL STILBENE DERIVATIVES AND METHODS OF USE | YALE UNIVERSITY | 2022-06-23 | — | — | US | disclosed |
| US-20220193080-A1 | ALLOSTERIC AGONISTS AND POSITIVE ALLOSTERIC MODULATORS OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR | UNIVERSITY OF THE SCIENCES (US) | 2022-06-23 | — | — | US | disclosed |
| US-20220194908-A1 | SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | RECEPTOS LLC | 2022-06-23 | — | — | US | disclosed |
| US-20220193242-A1 | IMMUNOPHILIN-DEPENDENT INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-06-23 | — | — | US | disclosed |
| WO-2022125989-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | SCRIPPS RESEARCH INSTITUTE, THE (US) | 2022-06-16 | — | — | WO | disclosed |
| EP-4009966-A1 | SCALEABLE PREPARATION OF POLYKETIDES | The Regents of the University of California (US) | 2022-06-15 | — | — | EP | disclosed |
| EP-4003351-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | City of Hope (US) | 2022-06-01 | — | — | EP | disclosed |
| US-20220160705-A1 | METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES | CORNELL UNIVERSITY | 2022-05-26 | — | — | US | disclosed |
| US-20220154271-A1 | COMPOSITIONS AND METHODS FOR NUCLEIC ACID SEQUENCING | FIRST-CITIZENS BANK & TRUST COMPANY | 2022-05-19 | — | — | US | disclosed |
| US-20220144788-A1 | SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | RECEPTOS LLC | 2022-05-12 | — | — | US | disclosed |
| US-11324731-B2 | TXNIP-TRX complex inhibitors and methods of using the same | CITY OF HOPE (US) | 2022-05-10 | — | — | US | disclosed |
| WO-2022093817-A1 | MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS, AND METHODS OF MAKING AND USING SAME | YALE UNIVERSITY (US) | 2022-05-05 | — | — | WO | disclosed |
| US-20220133747-A1 | ESTROGEN RECEPTOR INHIBITORS AND USES THEROF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-05-05 | — | — | US | disclosed |
| US-20220127299-A1 | NUCLEOTIDE CLEAVABLE LINKERS AND USES THEREOF | LG ELECTRONICS INC. (KR) | 2022-04-28 | — | — | US | disclosed |
| US-20220119709-A1 | HETEROARYL-THIO-SUBSTITUTED PYRONES | UNITED STATES DEPARTMENT OF ENERGY | 2022-04-21 | — | — | US | disclosed |
| US-20220119389-A1 | BERBAMINE DERIVATIVES AND METHODS OF USE THEREOF | CITY OF HOPE | 2022-04-21 | — | — | US | disclosed |
| US-20220119780-A1 | ENGINEERED PYROCOCCUS ENZYMES AND USES THEREOF | FIRST-CITIZENS BANK & TRUST COMPANY | 2022-04-21 | — | — | US | disclosed |
| US-20220119779-A1 | MODIFIED PYROCOCCUS POLYMERASES AND USES THEREOF | FIRST-CITIZENS BANK & TRUST COMPANY | 2022-04-21 | — | — | US | disclosed |
| EP-3983391-A1 | ACETYL-COA SYNTHETASE 2 (ACSS2) INHIBITORS AND METHODS USING SAME | The Wistar Institute (US) | 2022-04-20 | — | — | EP | disclosed |
| US-20220112166-A1 | Selective JAK2 Pseudokinase Ligands and Methods of Use | YALE UNIVERSITY | 2022-04-14 | — | — | US | disclosed |
| US-20220098210-A1 | QUINDOLINE COMPOUNDS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-31 | — | — | US | disclosed |
| EP-3968981-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE AND METABOLIC DISORDERS | The Scripps Research Institute (US) | 2022-03-23 | — | — | EP | disclosed |
| EP-3044216-B1 | NOVEL AND SPECIFIC INHIBITORS OF CYTOCHROME P450 26 RETINOIC ACID HYDROXYLASE | UNIV WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2022-02-23 | — | — | EP | disclosed |
| US-11247972-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2022-02-15 | — | — | US | disclosed |
| US-11236387-B2 | Compositions and methods for nucleic acid sequencing | Singular Genomics Systems, Inc. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20220029173-A1 | Carbon Nanomaterial Supported Single Atom Catalysts and Methods of Preparing Same | NATIONAL SCIENCE FOUNDATION | 2022-01-27 | — | — | US | disclosed |
| US-20220002231-A1 | PARG INHIBITORS AND METHOD OF USE THEREOF | CITY OF HOPE | 2022-01-06 | — | — | US | disclosed |
| US-20220002730-A1 | OLIGONUCLEOTIDE INHIBITORS OF NUCLEAR FACTOR KAPPA-LIGHT-CHAIN-ENHANCER OF ACTIVATED B CELLS AND THE USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-01-06 | — | — | US | disclosed |
| US-11207301-B2 | Sphingosine 1 phosphate receptor agonists for neuroprotection | RECEPTOS LLC (US) | 2021-12-28 | — | — | US | disclosed |
| WO-2021252665-A1 | HOLOGRAPHIC RECORDING MATERIALS AND METHODS OF MAKING SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2021-12-16 | — | — | WO | disclosed |
| US-20210387986-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-16 | — | — | US | disclosed |
| US-11191745-B2 | Silica nanoparticle with an insoluble drug | CITY OF HOPE (US) | 2021-12-07 | — | — | US | disclosed |
| US-20210371409-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2021-12-02 | — | — | US | disclosed |
| US-20210353626-A1 | BETA-ADRENERGIC RECEPTOR ALLOSTERIC MODULATORS | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2021-11-18 | — | — | US | disclosed |
| WO-2021222630-A1 | OXIDIZED POLYISOBUTENE COMPOUNDS AND METHODS OF MAKING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021222634-A1 | OXIDIZED POLYETHYLENE COMPOUNDS AND METHODS OF MAKING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-11-04 | — | — | WO | disclosed |
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | RAPT THERAPEUTICS INC (US) | 2021-10-14 | — | — | US | disclosed |
| US-20210317157-A1 | Substituted Alloxazine Nucleosides and Nucleotides, and Methods of Making Same | UNIV COLORADO REGENTS (US) | 2021-10-14 | — | — | US | disclosed |
| US-20210310002-A1 | CATIONIC COMPOUNDS FOR DELIVERY OF NUCLEIC ACIDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-10-07 | — | — | US | disclosed |
| US-11136565-B2 | Modified archaeal family B polymerases | Singular Genomics Systems, Inc. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20210300910-A1 | PHEBOX LIGANDS AND METHODS OF MAKING SAME | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2021-09-30 | — | — | US | disclosed |
| US-20210291154-A1 | DEHYDROGENATION OF SUBSTRATES BY TRANSITION METAL COMPLEXES | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY | 2021-09-23 | — | — | US | disclosed |
| US-20210284975-A1 | MODIFIED PYROCOCCUS POLYMERASES AND USES THEREOF | FIRST-CITIZENS BANK & TRUST COMPANY | 2021-09-16 | — | — | US | disclosed |
| WO-2021183791-A1 | WNT/CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | CITY OF HOPE (US) | 2021-09-16 | — | — | WO | disclosed |
| WO-2021163192-A1 | MYC INHIBITORS AND USES THEREOF | STEMSYNERGY THERAPEUTICS, INC. (US) | 2021-08-19 | — | — | WO | disclosed |
| WO-2021158899-A1 | ELONGATION FACTOR 1-ALPHA INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-08-12 | — | — | WO | disclosed |
| EP-2922829-B1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2021-08-11 | — | — | EP | disclosed |
| US-20210238167-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | CORNELL UNIVERSITY | 2021-08-05 | — | — | US | disclosed |
| WO-2021155004-A1 | STRAD-BINDING AGENTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-08-05 | — | — | WO | disclosed |
| US-11077435-B2 | Catalyst and method for fractionating lignocellulosic material | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-11072635-B2 | Macrocyclic broad spectrum antibiotics | RQX PHARMACEUTICALS, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-11072594-B2 | Trioxolane agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-07-27 | — | — | US | disclosed |
| US-20210214365-A1 | INHIBITORS OF CANCER INVASION, ATTACHMENT, AND/OR METASTASIS | Sanford Burnham Prebys Medical Discovery Institute | 2021-07-15 | — | — | US | disclosed |
| US-11052044-B2 | In situ lipid synthesis for protein reconstitution | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-07-06 | — | — | US | disclosed |
| US-20210198316-A9 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-07-01 | — | — | US | disclosed |
| US-20210198238-A1 | IRE1 KINASE INHIBITORS AND USES THEREOF | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2021-07-01 | — | — | US | disclosed |
| WO-2021133742-A1 | STABILIZATION OF MHC COMPLEXES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-07-01 | — | — | WO | disclosed |
| US-11046699-B2 | Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses | RAPT THERAPEUTICS, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-11040954-B1 | CXCR3 receptor agonists | RECEPTOS LLC (US) | 2021-06-22 | — | — | US | disclosed |
| WO-2021119199-A1 | ALPHA-5 BETA-1 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-17 | — | — | WO | disclosed |
| WO-2021119606-A1 | FLOW CHEMISTRY SYNTHESIS OF ISOCYANATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-17 | — | — | WO | disclosed |
| US-11034942-B1 | Modified pyrococcus polymerases and uses thereof | Singular Genomics Systems, Inc. (US) | 2021-06-15 | — | — | US | disclosed |
| US-11034691-B2 | Sphinogosine-1 -phosphate receptor modulators for treatment of cardiopulmonary disorders | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-06-15 | — | — | US | disclosed |
| US-20210171455-A1 | ALPHA-5 BETA-1 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-06-10 | — | — | US | disclosed |
| WO-2021108662-A1 | COMPOUND COMPRISING A NUCLEIC ACID AND A HALF-LIFE EXTENSION MOTIF | DTX PHARMA, INC. (US) | 2021-06-03 | — | — | WO | disclosed |
| US-20210155626-A1 | MODULATION OF IRE1 | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2021-05-27 | — | — | US | disclosed |
| WO-2021102299-A1 | CASPASE 6 INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-05-27 | — | — | WO | disclosed |
| WO-2021102359-A2 | TASPASE1 INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-05-27 | — | — | WO | disclosed |
| WO-2021102361-A1 | CASPASE 6 INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-05-27 | — | — | WO | disclosed |
| US-11008325-B2 | Inhibitors of cancer invasion, attachment, and/or metastasis | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2021-05-18 | — | — | US | disclosed |
| US-20210139771-A1 | Luminescent Compound | NATIONAL SCIENCE FOUNDATION | 2021-05-13 | — | — | US | disclosed |
| EP-3145944-B1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-10988461-B2 | Small molecule IRE1-α inhibitors | CORNELL UNIVERSITY (US) | 2021-04-27 | — | — | US | disclosed |
| WO-2021076617-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2021072246-A1 | ENGINEERED ANTIBODIES AS MOLECULAR DEGRADERS THROUGH CELLULAR RECEPTORS | YALE UNIVERSITY (US) | 2021-04-15 | — | — | WO | disclosed |
| US-20210102950-A1 | COMPOSITIONS AND METHODS FOR ENRICHMENT AND DETECTION OF UBIQUITIN AND UBIQUITIN CONJUGATES | YALE UNIVERSITY | 2021-04-08 | — | — | US | disclosed |
| WO-2021067604-A1 | QUINOLINE INHIBITORS OF RAD52 AND METHODS OF USE | DREXEL UNIVERSITY (US) | 2021-04-08 | — | — | WO | disclosed |
| US-20210101885-A1 | PROCESSES FOR THE PREPARATION OF PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR | ARENA PHARMACEUTICALS, INC. | 2021-04-08 | — | — | US | disclosed |
| US-20210079364-A1 | MODIFIED THERMOCCOCUS POLYMERASES | FIRST-CITIZENS BANK & TRUST COMPANY | 2021-03-18 | — | — | US | disclosed |
| WO-2021050556-A1 | COMPOSITIONS AND METHODS FOR INHIBITING RIBOSOME INACTIVATING PROTEINS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2021-03-18 | — | — | WO | disclosed |
| WO-2021035045-A1 | METTL16 INHIBITORS AND USES THEREOF | CITY OF HOPE (US) | 2021-02-25 | — | — | WO | disclosed |
| EP-3782991-A1 | NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS | The Scripps Research Institute (US) | 2021-02-24 | — | — | EP | disclosed |
| US-20210040555-A1 | COMPOSITIONS AND METHODS FOR NUCLEIC ACID SEQUENCING | FIRST-CITIZENS BANK & TRUST COMPANY | 2021-02-11 | — | — | US | disclosed |
| WO-2021026273-A1 | SCALEABLE PREPARATION OF POLYKETIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-02-11 | — | — | WO | disclosed |
| US-10913736-B2 | Specific inhibitors of methionyl-tRNA synthetase | UNIVERSITY OF WASHINGTON (US) | 2021-02-09 | — | — | US | disclosed |
| US-20210023238-A1 | TRIPTOLIDE ANTIBODY CONJUGATES | CITY OF HOPE | 2021-01-28 | — | — | US | disclosed |
| US-20210023065-A1 | AMPHIPHILIC THIOL COMPOUNDS AND USES THEREOF | UNIV CALIFORNIA (US) | 2021-01-28 | — | — | US | disclosed |
| WO-2021016464-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | CITY OF HOPE (US) | 2021-01-28 | — | — | WO | disclosed |
| US-20210002325-A1 | BIOREACTIVE COMPOSITIONS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-01-07 | — | — | US | disclosed |
| EP-3406142-B1 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | CELGENE INT II SARL (CH) | 2020-12-23 | — | — | EP | disclosed |
| WO-2020251953-A1 | STREPTOGRAMIN COMPOSITIONS AND THE USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020252407-A1 | ACETYL-COA SYNTHETASE 2 (ACSS2) INHIBITORS AND METHODS USING SAME | THE WISTAR INSTITUTE (US) | 2020-12-17 | — | — | WO | disclosed |
| EP-3008056-B1 | NOVEL GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-12-09 | — | — | EP | disclosed |
| WO-2020232255-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE AND METABOLIC DISORDERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-11-19 | — | — | WO | disclosed |
| US-20200360541-A1 | ELECTROCHEMICAL FLASH FLUORINATION AND RADIOFLUORINATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-11-19 | — | — | US | disclosed |
| US-10822653-B1 | Nucleotide cleavable linkers and uses thereof | Singular Genomics Systems, Inc. (US) | 2020-11-03 | — | — | US | disclosed |
| US-10822340-B2 | Substituted imidazolopyrazine compounds and methods of using same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-11-03 | — | — | US | disclosed |
| US-20200340051-A1 | NUCLEOTIDE CLEAVABLE LINKERS AND USES THEREOF | FIRST-CITIZENS BANK & TRUST COMPANY | 2020-10-29 | — | — | US | disclosed |
| US-20200338541-A1 | CATALYST AND METHOD FOR FRACTIONATING LIGNOCELLULOSIC MATERIAL | WISYS TECH FOUNDATION INC (US) | 2020-10-29 | — | — | US | disclosed |
| US-20200325177-A1 | METHODS OF MAKING STREPTOGRAMIN COMPOSITIONS AND THE USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-10-15 | — | — | US | disclosed |
| US-20200316010-A1 | SILICA NANOPARTICLE WITH AN INSOLUBLE DRUG | CITY OF HOPE | 2020-10-08 | — | — | US | disclosed |
| US-10787437-B2 | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-HT2A serotonin receptor | ARENA PHARMACEUTICALS, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20200297725-A1 | ALLOSTERIC BCR-ABL PROTEOLYSIS TARGETING CHIMERIC COMPOUNDS | YALE UNIVERSITY | 2020-09-24 | — | — | US | disclosed |
| EP-2791112-B1 | CARBOXYLIC ACID DERIVATIVES COMPRISING FOUR CYCLES ACTING AS GLP-1 RECEPTOR MODULATORS FOR THERAPY OF DISEASES SUCH AS DIABETES | CELGENE INT II SÀRL (CH) | 2020-09-23 | — | — | EP | disclosed |
| EP-3230276-B1 | GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-09-02 | — | — | EP | disclosed |
| EP-3097092-B1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | CLEAVE BIOSCIENCES INC (US) | 2020-08-26 | — | — | EP | disclosed |
| US-20200262869-A1 | PEPTIDE ANTIBIOTIC COMPLEXES AND METHODS OF USE THEREOF | GENENTECH, INC. | 2020-08-20 | — | — | US | disclosed |
| US-10744117-B2 | PPARG modulators for the treatment of osteoporosis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-08-18 | — | — | US | disclosed |
| WO-2020163594-A1 | IMMUNOPHILIN BINDING AGENTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-08-13 | — | — | WO | disclosed |
| US-10737256-B2 | Catalyst and method for fractionating lignocellulosic material | ALKASRAWI MALEK (US) | 2020-08-11 | — | — | US | disclosed |
| US-10738072-B1 | Nucleotide analogues | Singular Genomics Systems, Inc. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20200239519-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. | 2020-07-30 | — | — | US | disclosed |
| US-10722514-B2 | Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof | RAPT THERAPEUTICS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20200222557-A1 | COMPOSITIONS AND METHODS OF MODULATING MACROPHAGE ACTIVITY | CITY OF HOPE | 2020-07-16 | — | — | US | disclosed |
| US-20200223803-A1 | Compositions and Methods for Treating Toxoplasmosis, Cryptosporidiosis, and Other Apicomplexan Protozoan Related Diseases | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2020-07-16 | — | — | US | disclosed |
| US-10703843-B2 | Compositions and methods for bonding glues, adhesives, and coatings to surfaces | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2020-07-07 | — | — | US | disclosed |
| EP-3172199-B1 | PYRIMIDINE DERIVATIVES AS GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-07-01 | — | — | EP | disclosed |
| EP-3661504-A1 | METHODS OF MAKING STREPTOGRAMIN COMPOSITIONS AND THE USE THEREOF | The Regents of The University of California (US) | 2020-06-10 | — | — | EP | disclosed |
| US-20200140406-A1 | TRIOXOLANE AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-05-07 | — | — | US | disclosed |
| US-10632122-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases | UNIVERSITY OF WASHINGTON (US) | 2020-04-28 | — | — | US | disclosed |
| US-20200085800-A1 | TXNIP-TRX COMPLEX INHIBITORS AND METHODS OF USING THE SAME | CITY OF HOPE | 2020-03-19 | — | — | US | disclosed |
| US-20200085795-A1 | SPHINGOSINE 1 PHOSPHATE RECEPTOR AGONISTS FOR NEUROPROTECTION | RECEPTOS LLC | 2020-03-19 | — | — | US | disclosed |
| US-20200080065-A1 | MODIFIED ARCHAEAL FAMILY B POLYMERASES | FIRST-CITIZENS BANK & TRUST COMPANY | 2020-03-12 | — | — | US | disclosed |
| US-20200079793-A1 | COMPOUNDS AND METHODS FOR MODULATING ADENOSINE A2B RECEPTOR AND ADENOSINE A2A RECEPTOR | CORVUS PHARMACEUTICALS, INC. | 2020-03-12 | — | — | US | disclosed |
| EP-3615524-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | Celgene International II Sàrl (CH) | 2020-03-04 | — | — | EP | disclosed |
| EP-3616753-A1 | COMPOUNDS FOR MODULATING ADENOSINE A2B RECEPTOR AND ADENOSINE A2A RECEPTOR | Corvus Pharmaceuticals, Inc. (US) | 2020-03-04 | — | — | EP | disclosed |
| US-20200055972-A1 | Photosensitive Resin and Manufacturing Method Thereof | DAQRI, LLC | 2020-02-20 | — | — | US | disclosed |
| US-20200048668-A1 | BIOLOGICAL PRODUCTION OF ß-LACTONES | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2020-02-13 | — | — | US | disclosed |
| US-10550210-B2 | Polyisocyanates from fused bicyclic polyols and polyurethanes therefrom | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| WO-2020023802-A1 | PARG INHIBITORS AND METHOD OF USE THEREOF | CITY OF HOPE (US) | 2020-01-30 | — | — | WO | disclosed |
| US-10544104-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases | University of Washington Through its Center for Co (US) | 2020-01-28 | — | — | US | disclosed |
| US-10544136-B2 | Modulators of sphingosine phosphate receptors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190352508-A1 | SILICON CONTAINING DETECTABLE COMPOUNDS | FIRST-CITIZENS BANK & TRUST COMPANY | 2019-11-21 | — | — | US | disclosed |
| US-20190345133-A1 | CXCR3 RECEPTOR AGONISTS | RECEPTOS LLC | 2019-11-14 | — | — | US | disclosed |
| US-10465029-B2 | Photosensitive resin and manufacturing method thereof | Pacific Light & Hologram, Inc. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190300527-A1 | SPHINOGOSINE-1-PHOSPHATE RECEPTOR MODULATORS FOR TREATMENT OF CARDIOPULMONARY DISORDERS | THE SCRIPPS RESEARCH INSTITUTE | 2019-10-03 | — | — | US | disclosed |
| US-10414903-B2 | Methods for synthesis of end-functionalized polyolefins | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-09-17 | — | — | US | disclosed |
| US-20190263824-A1 | INHIBITORS OF CANCER INVASION, ATTACHMENT, AND/OR METASTASIS | VIRGINIA COMMONWEALTH UNIVERSITY | 2019-08-29 | — | — | US | disclosed |
| EP-2706999-B1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2019-08-28 | — | — | EP | disclosed |
| US-10392422-B2 | Macrocyclic broad spectrum antibiotics | RQX PHARMACEUTICALS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-20190241692-A1 | PHOTOSENSITIVE RESIN AND MANUFACTURING METHOD THEREOF | DUALITAS LTD. (GB) | 2019-08-08 | — | — | US | disclosed |
| US-20190224172-A1 | COMPOUNDS AND METHODS FOR TREATING LUPUS | RECEPTOS LLC | 2019-07-25 | — | — | US | disclosed |
| EP-2884978-B1 | NOVEL KAPPA OPIOID LIGANDS | SCRIPPS RESEARCH INST (US) | 2019-07-17 | — | — | EP | disclosed |
| US-10351595-B2 | — | — | 2019-07-16 | — | — | US | disclosed |
| US-10350211-B2 | Bumped kinase inhibitor compositions and methods for treating cancer | UNIVERSITY OF WASHINGTON (US) | 2019-07-16 | — | — | US | disclosed |
| EP-3507275-A1 | CXCR3 RECEPTOR AGONISTS | Celgene International II Sarl (CH) | 2019-07-10 | — | — | EP | disclosed |
| US-10323029-B2 | Sphinogosine-1-phosphate receptor modulators for treatment of cardiopulmonary disorders | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-06-18 | — | — | US | disclosed |
| US-10307425-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases | UNIVERSITY OF WASHINGTON (US) | 2019-06-04 | — | — | US | disclosed |
| EP-2850068-B1 | N-(phenyl)-2-[[3-(phenyl)-1H-1,2,4-triazol-5-yl]thio]-acetamide derivatives and related compounds as G protein coupled receptor 17 (GPCR17) modulators for use in the treatment of neuro-degenerative diseases | UNIV DEGLI STUDI MILANO (IT) | 2019-05-29 | — | — | EP | disclosed |
| US-20190142834-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2019-05-16 | — | — | US | disclosed |
| US-10280241-B2 | Tackifier compounds and methods of using the same | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-10266503-B1 | Sulfoxide ligand metal catalyzed oxidation of olefins | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-04-23 | — | — | US | disclosed |
| US-10259823-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2019-04-16 | — | — | US | disclosed |
| US-10239846-B2 | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | CELGENE INTERNATIONAL II SÀRL (CH) | 2019-03-26 | — | — | US | disclosed |
| US-20190084989-A1 | MODULATION OF IRE1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-03-21 | — | — | US | disclosed |
| US-20190084947-A1 | NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS | THE SCRIPPS RESEARCH INSTITUTE | 2019-03-21 | — | — | US | disclosed |
| WO-2019028084-A1 | METHODS OF MAKING STREPTOGRAMIN COMPOSITIONS AND THE USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-02-07 | — | — | WO | disclosed |
| US-20190023691-A1 | PROCESSES FOR THE PREPARATION OF PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR | ARENA PHARMACEUTICALS, INC. | 2019-01-24 | — | — | US | disclosed |
| US-20190022632-A1 | CATALYST AND METHOD FOR FRACTIONATING LIGNOCELLULOSIC MATERIAL | ALKASRAWI MALEK (US) | 2019-01-24 | — | — | US | disclosed |
| US-20190016706-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | CORNELL UNIVERSITY | 2019-01-17 | — | — | US | disclosed |
| EP-2600864-B1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISEASES | UNIV VIRGINIA PATENT FOUNDATION (US) | 2019-01-09 | — | — | EP | disclosed |
| US-10174005-B2 | Fused pyrimidines as inhibitors of p97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180369196-A1 | PPARG Modulators for the Treatment of Osteoporosis | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2018-12-27 | — | — | US | disclosed |
| WO-2018237296-A1 | PARG INHIBITORS AND METHOD OF USE THEREOF | CITY OF HOPE (US) | 2018-12-27 | — | — | WO | disclosed |
| EP-3406142-A1 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | Celgene International II Sàrl (CH) | 2018-11-28 | — | — | EP | disclosed |
| US-10131668-B2 | Substituted imidazo[1,5-a]pYRAZINES for modulation of IRE1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-11-20 | — | — | US | disclosed |
| US-20180327367-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | WUXI APPTEC CO., LTD (CN) | 2018-11-15 | — | — | US | disclosed |
| US-10125123-B2 | Small molecule IRE1-α inhibitors | CORNELL UNIVERSITY (US) | 2018-11-13 | — | — | US | disclosed |
| US-10118915-B2 | Kappa opioid ligands | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-11-06 | — | — | US | disclosed |
| WO-2018200833-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | CELGENE INTERNATIONAL II SARL (CH) | 2018-11-01 | — | — | WO | disclosed |
| US-20180298023-A1 | POLYISOCYANATES FROM FUSED BICYCLIC POLYOLS AND POLYURETHANES THEREFROM | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2018-10-18 | — | — | US | disclosed |
| US-20180271871-A1 | BUMPED KINASE INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-09-27 | — | — | US | disclosed |
| US-20180273537-A1 | COMPOSITIONS AND METHODS FOR TREATING TOXOPLASMOSIS, CRYPTOSPORIDIOSIS AND OTHER APICOMPLEXAN PROTOZOAN RELATED DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-09-27 | — | — | US | disclosed |
| US-10081638-B2 | Polyisocyanates from fused bicyclic polyols and polyurethanes therefrom | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2018-09-25 | — | — | US | disclosed |
| WO-2018161033-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | WRIGHT, ADRIAN (GB) | 2018-09-07 | — | — | WO | disclosed |
| EP-3366680-A1 | DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES | Parion Sciences, Inc. (US) | 2018-08-29 | — | — | EP | disclosed |
| US-10059691-B2 | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-HT2A serotonin receptor | ARENA PHARMACEUTICALS, INC. (US) | 2018-08-28 | — | — | US | disclosed |
| US-10034886-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2018-07-31 | — | — | US | disclosed |
| US-10016394-B2 | PPARG modulators for treatment of osteoporosis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-07-10 | — | — | US | disclosed |
| US-10010554-B2 | Fused pyrimidines as inhibitors of P97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| WO-2018112435-A1 | COMPOUNDS FOR THE INHIBITION OF A PROLYL ISOMERASE AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-06-21 | — | — | WO | disclosed |
| US-20180148524-A1 | TACKIFIER COMPOUNDS AND METHODS OF USING THE SAME | IOWA STATE UNIV RESEACH FOUNDATION INC (US) | 2018-05-31 | — | — | US | disclosed |
| US-9975863-B2 | Modulators of sphingosine phosphate receptors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-05-22 | — | — | US | disclosed |
| US-20180134873-A1 | METHODS FOR SYNTHESIS OF END-FUNCTIONALIZED POLYOLEFINS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-05-17 | — | — | US | disclosed |
| US-9963439-B2 | Specific inhibitors of cytochrome P450 26 retinoic acid hydroxylase | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2018-05-08 | — | — | US | disclosed |
| US-9956214-B2 | 5-aminopyrazole-4-carboxamide inhibitors of CDPK1 from T. gondii and C. parvum | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2018-05-01 | — | — | US | disclosed |
| US-20180111907-A1 | DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES | PARION SCIENCES, INC. | 2018-04-26 | — | — | US | disclosed |
| EP-2498609-B1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2018-04-18 | — | — | EP | disclosed |
| US-20180099954-A1 | NOVEL KAPPA OPIOID LIGANDS | SCRIPPS RESEARCH INST (US) | 2018-04-12 | — | — | US | disclosed |
| EP-2811997-B1 | SUBSTITUTED PROLINES/PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | EOLAS THERAPEUTICS INC (US) | 2018-04-11 | — | — | EP | disclosed |
| WO-2018064498-A1 | METHODS OF TREATING EPILEPSY AND RELATED NEUROLOGICAL CONDITIONS | PAIRNOMIX, LLC (US) | 2018-04-05 | — | — | WO | disclosed |
| US-9920145-B2 | Tackifier compounds and methods of using the same | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-20180072675-A1 | ANTIMICROBIAL PYRIDINOHYDRAZIDE AND HYDRAZOMETHYLPYRIDINE-BASED AGENTS | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE | 2018-03-15 | — | — | US | disclosed |
| WO-2018045246-A1 | CXCR3 RECEPTOR AGONISTS | CELGENE INTERNATIONAL II SARL (CH) | 2018-03-08 | — | — | WO | disclosed |
| US-9896452-B2 | Substituted prolines/piperidines as orexin receptor antagonists | EOLAS THERAPEUTICS, INC. (US) | 2018-02-20 | — | — | US | disclosed |
| US-20180044325-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | CLEAVE BIOSCIENCES, INC. | 2018-02-15 | — | — | US | disclosed |
| EP-2875018-B1 | FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX | CLEAVE BIOSCIENCES INC (US) | 2018-02-14 | — | — | EP | disclosed |
| US-9878988-B2 | Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases | PARION SCIENCES, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9879030-B2 | GPR17 receptor modulators | UNIVERSITA′ DEGLI STUDI DI MILANO (IT) | 2018-01-30 | — | — | US | disclosed |
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2018-01-25 | — | — | US | disclosed |
| US-20180022709-A1 | Compositions and Methods for Treating Toxoplasmosis, Cryptosporidiosis, and Other Apicomplexan Protozoan Related Diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-01-25 | — | — | US | disclosed |
| US-9874566-B2 | Compositions and methods for making and using oxygen sensing nanofibers and scaffolds | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2018-01-23 | — | — | US | disclosed |
| US-9868722-B2 | Monocyclic pyrimidine/pyridine compounds as inhibitors of P97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-20180009770-A1 | NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS | THE SCRIPPS RESEARCH INSTITUTE | 2018-01-11 | — | — | US | disclosed |
| EP-2498611-B1 | SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | CELGENE INT II SÀRL (CH) | 2018-01-10 | — | — | EP | disclosed |
| US-20170362363-A1 | COMPOSITIONS AND METHODS FOR BONDING GLUES, ADHESIVES, AND COATINGS TO SURFACES | UNIVERSITY OF VIRGINIA | 2017-12-21 | — | — | US | disclosed |
| WO-2017214534-A1 | SYNTHESIS OF THE ARYLOMYCIN MACROCYCLIC CORE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-12-14 | — | — | WO | disclosed |
| US-9839664-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-12-12 | — | — | US | disclosed |
| US-20170342451-A1 | BIOSYNTHESIS OF PACLITAXEL INTERMEDIATE | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2017-11-30 | — | — | US | disclosed |
| US-9828363-B2 | Fused pyrimidines as inhibitors of P97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20170327512-A1 | MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL | SCRIPPS RESEARCH INST (US) | 2017-11-16 | — | — | US | disclosed |
| US-20170320839-A1 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | RECEPTOS LLC | 2017-11-09 | — | — | US | disclosed |
| US-20170313717-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2017-11-02 | — | — | US | disclosed |
| WO-2012158550-A9 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | RECEPTOS, INC. (US) | 2017-10-26 | — | — | WO | disclosed |
| US-9795613-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-10-24 | — | — | US | disclosed |
| US-20170275279-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | UNIVERSITY OF WASHINGTON | 2017-09-28 | — | — | US | disclosed |
| US-20170275334-A1 | LINEAR PEPTIDE ANTIBIOTICS | RQX PHARMACEUTICALS, INC. | 2017-09-28 | — | — | US | disclosed |
| US-20170267679-A1 | TRICYCLIC FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF p97 COMPLEX | CLEAVE BIOSCIENCES INC (US) | 2017-09-21 | — | — | US | disclosed |
| US-9765037-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170258795-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | CLEAVE THERAPEUTICS, INC. | 2017-09-14 | — | — | US | disclosed |
| US-20170253590-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | CORNELL UNIVERSITY | 2017-09-07 | — | — | US | disclosed |
| US-20170252350-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | CORNELL UNIVERSITY | 2017-09-07 | — | — | US | disclosed |
| EP-3208270-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | Cleave Biosciences, Inc. (US) | 2017-08-23 | — | — | EP | disclosed |
| US-9732365-B2 | Biosynthesis of paclitaxel intermediate | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2017-08-15 | — | — | US | disclosed |
| US-20170226243-A1 | TACKIFIER COMPOUNDS AND METHODS OF USING THE SAME | UNIV IOWA STATE RES FOUND INC (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170216392-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2017-08-03 | — | — | US | disclosed |
| US-20170217963-A1 | SPHINOGOSINE-1-PHOSPHATE RECEPTOR MODULATORS FOR TREATMENT OF CARDIOPULMONARY DISORDERS | THE SCRIPPS RESEARCH INSTITUTE | 2017-08-03 | — | — | US | disclosed |
| US-9708368-B2 | Linear peptide antibiotics | RQX PHARMACEUTICALS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9700543-B2 | GLP-1 receptor stabilizers and modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-07-11 | — | — | US | disclosed |
| US-9688794-B2 | Tackifier compounds and methods of using the same | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-9682966-B2 | Kappa opioid ligands | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-06-20 | — | — | US | disclosed |
| US-20170165259-A1 | COMBINED MODULATION OF IRE1 | NIH-DEITR | 2017-06-15 | — | — | US | disclosed |
| US-20170165236-A1 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND COMBINATION THERAPY THEREWITH | RECEPTOS LLC | 2017-06-15 | — | — | US | disclosed |
| EP-3172199-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | Receptos, Inc. (US) | 2017-05-31 | — | — | EP | disclosed |
| US-9656994-B2 | Substituted benzimidazoles as nociceptin receptor modulators | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-05-23 | — | — | US | disclosed |
| US-20170137408-A1 | PROCESSES FOR THE PREPARATION OF PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR | ARENA PHARMACEUTICALS, INC. | 2017-05-18 | — | — | US | disclosed |
| EP-2830614-B1 | CYCLIC PRODRUGS OF DUOCARMYCIN ANALOGS | SCRIPPS RESEARCH INST (US) | 2017-04-26 | — | — | EP | disclosed |
| US-20170101410-A1 | SUBSTITUTED PROLINES / PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | EOLAS THERAPEUTICS, INC. | 2017-04-13 | — | — | US | disclosed |
| US-9617197-B2 | Compositions and methods for treating inflammatory diseases | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2017-04-11 | — | — | US | disclosed |
| US-20170088582-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-9598430-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-03-21 | — | — | US | disclosed |
| US-20170073370-A1 | BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. | 2017-03-16 | — | — | US | disclosed |
| EP-2713722-B1 | NOVEL GLP-1 RECEPTOR STABILIZERS AND MODULATORS | RECEPTOS LLC (US) | 2017-03-15 | — | — | EP | disclosed |
| US-9586928-B2 | Modulators of the nuclear hormone receptor ROR | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-03-07 | — | — | US | disclosed |
| US-20170056389-A1 | 5-AMINOPYRAZOLE-4-CARBOXAMIDE INHIBITORS OF CDPK1 FROM T. GONDII AND C. PARVUM | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2017-03-02 | — | — | US | disclosed |
| US-9580439-B2 | Inhibitors of focal adhesion kinase | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-02-28 | — | — | US | disclosed |
| US-20170050941-A1 | NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-02-23 | — | — | US | disclosed |
| US-20170044178-A1 | POLYISOCYANATES FROM FUSED BICYCLIC POLYOLS AND POLYURETHANES THEREFROM | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170035730-A1 | PPARG MODULATORS FOR TREATMENT OF OSTEOPOROSIS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2017-02-09 | — | — | US | disclosed |
| US-9556293-B2 | Polyisocyanates from fused bicyclic polyols and polyurethanes therefrom | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556149-B2 | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-HT2A serotonin receptor | ARENA PHARMACEUTICALS, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| WO-2016200840-A1 | MONO AND BICYCLIC RING BORONIC ACID, ESTER AND SALT COMPOUNDS AS INHIBITORS OF P97 COMPLEX | CLEAVE BIOSCIENCES, INC. (US) | 2016-12-15 | — | — | WO | disclosed |
| US-9518026-B2 | 5-aminopyrazole-4-carboxamide inhibitors of CDPK1 from T. gondii and C. parvum | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2016-12-13 | — | — | US | disclosed |
| US-20160355503-A1 | NITROGEN HEXACYCLE COMPOUNDS AS INHIBITORS OF p97 COMPLEX | CLEAVE BIOSCIENCES, INC. | 2016-12-08 | — | — | US | disclosed |
| US-9504675-B2 | Alpha-ketoheterocycles and methods of making and using | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-11-29 | — | — | US | disclosed |
| US-9499517-B2 | Substituted prolines / piperidines as orexin receptor antagonists | EOLAS THERAPEUTICS, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20160332990-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | CLEAVE BIOSCIENCES, INC. (US) | 2016-11-17 | — | — | US | disclosed |
| US-9493464-B2 | Wee1 degradation inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-11-15 | — | — | US | disclosed |
| EP-2528919-B1 | COMPOSITIONS AND METHODS FOR TREATING TOXOPLASMOSIS. CRYPTOSPORIDIOSIS AND OTHER APICOMPLEXAN PROTOZOAN RELATED DISEASES | UNIV WASHINGTON (US) | 2016-11-02 | — | — | EP | disclosed |
| US-9481659-B2 | Selective heterocyclic sphingosine 1 phosphate receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2016-11-01 | — | — | US | disclosed |
| US-20160310471-A1 | NOVEL GLP-1 RECEPTOR STABILIZERS AND MODULATORS | RECEPTOS LLC | 2016-10-27 | — | — | US | disclosed |
| US-9474755-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SARL (CH) | 2016-10-25 | — | — | US | disclosed |
| US-9475824-B2 | Fused pyrimidines as inhibitors of p97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2016-10-25 | — | — | US | disclosed |
| US-20160304495-A1 | MONOCYCLIC PYRIMIDINE/PYRIDINE COMPOUNDS AS INHIBITORS OF P97 COMPLEX | CLEAVE BIOSCIENCES, INC. (US) | 2016-10-20 | — | — | US | disclosed |
| US-20160297851-A1 | BROAD SPECTRUM ANTIBIOTIC ARYLOMYCIN ANALOGS | NAVY, SECRETARY OF THE UNITED STATES OF AMERICA | 2016-10-13 | — | — | US | disclosed |
| US-9440982-B2 | Substituted prolines/piperidines as orexin receptor antagonists | EOLAS THERAPEUTICS, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9427408-B2 | Silica-matrix forming compositions, materials formed therefrom, and methods of using the same | Kasinkas, Lisa (US) | 2016-08-30 | — | — | US | disclosed |
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-08-11 | — | — | US | disclosed |
| US-20160214993-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-07-28 | — | — | US | disclosed |
| US-9394264-B2 | Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | RECEPTOS, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20160200703-A1 | NOVEL AND SPECIFIC INHIBITORS OF CYTOCHROME P450 26 RETINOIC ACID HYDROXYLASE | UNIVERSITY OF MONTANA (US) | 2016-07-14 | — | — | US | disclosed |
| US-9388147-B2 | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | Celgene International II Sárl (CH) | 2016-07-12 | — | — | US | disclosed |
| US-20160194358-A1 | LINEAR PEPTIDE ANTIBIOTCS | RQX PHARMACEUTICALS, INC. | 2016-07-07 | — | — | US | disclosed |
| US-9382217-B2 | Modulators of sphingosine phosphate receptors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-07-05 | — | — | US | disclosed |
| US-9359588-B2 | Multilayered structure including cyclic olefin polymer or copolymer, and photobioreactor including the same | RAVEN INDUSTRIES, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20160122306-A1 | DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES | PARION SCIENCES, INC. (US) | 2016-05-05 | — | — | US | disclosed |
| US-9309285-B2 | Macrocyclic broad spectrum antibiotics | RQX PHARMACEUTICALS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-9309227-B2 | N-biphenylmethylbenzimidazole modulators of PPARG | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-04-12 | — | — | US | disclosed |
| US-20160090362-A1 | 5-AMINOPYRAZOLE-4-CARBOXAMIDE INHIBITORS OF CDPK1 FROM T. GONDII AND C. PARVUM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-31 | — | — | US | disclosed |
| US-9278910-B2 | GLP-1 receptor stabilizers and modulators | RECEPTOS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20160052913-A1 | SUBSTITUTED BENZIMIDAZOLES AS NOCICEPTIN RECEPTOR MODULATORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2016-02-25 | — | — | US | disclosed |
| US-9260427-B2 | GLP-1 receptor modulators | RECEPTOS, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-9260398-B2 | Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases | PARION SCIENCES, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20160038487-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-02-11 | — | — | US | disclosed |
| US-20160041177-A1 | COMPOSITIONS AND METHODS FOR MAKING AND USING OXYGEN SENSING NANOFIBERS AND SCAFFOLDS | Univ Virginia Patent Found (US) | 2016-02-11 | — | — | US | disclosed |
| US-9249128-B2 | Anti-cancer serine hydrolase inhibitory carbamates | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-02-02 | — | — | US | disclosed |
| US-20160024094-A1 | MODULATION OF IRE1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-01-28 | — | — | US | disclosed |
| WO-2016015014-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS, INC. (US) | 2016-01-28 | — | — | WO | disclosed |
| US-20150376198-A1 | MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-12-31 | — | — | US | disclosed |
| US-9187524-B2 | Broad spectrum antibiotic arylomycin analogs | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187522-B2 | GLP-1 receptor modulators | RECEPTOS, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9175061-B2 | Protein conjugates and methods for their preparation | NOVO NORDISK HEALTH CARE AG (CH) | 2015-11-03 | — | — | US | disclosed |
| US-20150299179-A1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | RECEPTOS, INC. (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150299150-A1 | SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | RECEPTOS LLC | 2015-10-22 | — | — | US | disclosed |
| WO-2015161108-A1 | PPARG MODULATORS FOR TREATMENT OF OSTEOPOROSIS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-10-22 | — | — | WO | disclosed |
| US-20150299149-A1 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | RECEPTOS LLC | 2015-10-22 | — | — | US | disclosed |
| US-20150284751-A1 | BIOSYNTHESIS OF PACLITAXEL INTERMEDIATE | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2015-10-08 | — | — | US | disclosed |
| US-20150274729-A1 | WEE1 DEGRADATION INHIBITORS | UNIVERSITY OF FLORIDA BOARD OF TRUSTEES | 2015-10-01 | — | — | US | disclosed |
| US-20150274880-A1 | POLYISOCYANATES FROM FUSED BICYCLIC POLYOLS AND POLYURETHANES THEREFROM | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2015-10-01 | — | — | US | disclosed |
| US-20150274861-A1 | TACKIFIER COMPOUNDS AND METHODS OF USING THE SAME | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2015-10-01 | — | — | US | disclosed |
| US-9139596-B2 | Cyclic prodrugs of duocarmycin analogs | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-09-22 | — | — | US | disclosed |
| US-RE45670-E1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2015-09-15 | — | — | US | disclosed |
| US-20150252037-A1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | RECEPTOS LLC | 2015-09-10 | — | — | US | disclosed |
| EP-2670245-B1 | ALPHA-KETOHETEROCYCLES AND METHODS OF MAKING AND USING | SCRIPPS RESEARCH INST (US) | 2015-09-09 | — | — | EP | disclosed |
| EP-2913326-A1 | Novel modulators of sphingosine phosphate receptors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-09-02 | — | — | EP | disclosed |
| US-20150239907-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | CLEAVE THERAPEUTICS, INC. | 2015-08-27 | — | — | US | disclosed |
| US-20150239918-A1 | FUNCTIONALIZED CARBON MATRIX MATERIALS | NATIONAL SCIENCE FOUNDATION | 2015-08-27 | — | — | US | disclosed |
| US-20150210673-A1 | NOVEL KAPPA OPIOID LIGANDS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-07-30 | — | — | US | disclosed |
| US-9074129-B2 | Mechanochromic luminescent difluoroboron beta-diketonates | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2015-07-07 | — | — | US | disclosed |
| US-9062026-B2 | Fused pyrimidines and substituted quinazolines as inhibitors of p97 | CLEAVE BIOSCIENCES, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20150166605-A1 | LINEAR PEPTIDE ANTIBIOTICS | RQX PHARMACEUTICALS, INC. | 2015-06-18 | — | — | US | disclosed |
| US-9051265-B2 | N-benzylindole modulators of PPARG | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-06-09 | — | — | US | disclosed |
| EP-2875018-A1 | FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX | Cleave Biosciences, Inc. (US) | 2015-05-27 | — | — | EP | disclosed |
| US-20150141410-A1 | GPR17 Receptor Modulators | UNIVERSITA' DEGLI STUDI DI MILANO (IT) | 2015-05-21 | — | — | US | disclosed |
| US-20150141464-A1 | N-BIPHENYLMETHYLBENZIMIDAZOLE MODULATORS OF PPARG | SCRIPPS RESEARCH INSTITUTE, THE | 2015-05-21 | — | — | US | disclosed |
| US-9023964-B2 | Conjugated polymer and semiconductor devices including the same | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20150099764-A1 | DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES | PARION SCIENCES, INC. (US) | 2015-04-09 | — | — | US | disclosed |
| US-8999922-B2 | Linear peptide antibiotics | RQX PHARMACEUTICALS, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-8993665-B2 | Amphiphilic multi-arm copolymers and nanomaterials derived therefrom | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8980898-B2 | Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases | PARION SCIENCES, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20150057270-A1 | CYCLIC PRODRUGS OF DUOCARMYCIN ANALOGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-26 | — | — | US | disclosed |
| US-20150057307-A1 | NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-26 | — | — | US | disclosed |
| US-8957093-B2 | N-biphenylmethylindole modulators of PPARG | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-02-17 | — | — | US | disclosed |
| US-20150045286-A1 | BROAD SPECTRUM ANTIBIOTIC ARYLOMYCIN ANALOGS | NAVY, SECRETARY OF THE UNITED STATES OF AMERICA | 2015-02-12 | — | — | US | disclosed |
| US-20150045372-A1 | PROCESSES FOR THE PREPARATION OF PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR | ARENA PHARMACEUTICALS, INC. | 2015-02-12 | — | — | US | disclosed |
| US-20150038416-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2015-02-05 | — | — | US | disclosed |
| US-20150011527-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2015-01-08 | — | — | US | disclosed |
| US-20140364433-A1 | SUBSTITUTED PROLINES / PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-12-11 | — | — | US | disclosed |
| US-20140364432-A1 | SUBSTITUTED PROLINES / PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-12-11 | — | — | US | disclosed |
| US-8895776-B2 | Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20140336185-A1 | NOVEL GLP-1 RECEPTOR STABILIZERS AND MODULATORS | RECEPTOS LLC | 2014-11-13 | — | — | US | disclosed |
| US-20140302130-A1 | SILICA-MATRIX FORMING COMPOSITIONS, MATERIALS FORMED THEREFROM, AND METHODS OF USING THE SAME | KASINKAS, Lisa | 2014-10-09 | — | — | US | disclosed |
| US-RE45183-E1 | Heteroaryl-ureas and their use as glucokinase activators | NOVO NORDISK A/S (DK) | 2014-10-07 | — | — | US | disclosed |
| US-20140288090-A1 | N-ARYLYLMETHYLINDAZOLE MODULATORS OF PPARG | SCRIPPS RESEARCH INSTITUTE, THE | 2014-09-25 | — | — | US | disclosed |
| EP-1531815-B1 | GLUCOKINASE ACTIVATORS | NOVO NORDISK AS (DK) | 2014-09-24 | — | — | EP | disclosed |
| EP-1997533-B1 | Heterocyclic boronic acid compounds, dipeptidyl peptidase IV inhibitors | PHENOMIX CORP (US) | 2014-09-24 | — | — | EP | disclosed |
| US-20140275459-A1 | CONJUGATED POLYMER AND SEMICONDUCTOR DEVICES INCLUDING THE SAME | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140249196-A1 | N-BENZYLBENZIMIDAZOLE MODULATORS OF PPARG | SCRIPPS RESEARCH INSTITUTE, THE | 2014-09-04 | — | — | US | disclosed |
| US-20140249073-A1 | BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC (US) | 2014-09-04 | — | — | US | disclosed |
| EP-1689757-B1 | HETEROCYCLIC BORONIC ACID COMPOUNDS | PHENOMIX CORP (US) | 2014-08-27 | — | — | EP | disclosed |
| US-8816121-B2 | GLP-1 receptor stabilizers and modulators | RECEPTOS, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-20140235548-A1 | COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION | CLEAVE BIOSCIENCES, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-8796318-B2 | Modulators of sphingosine phosphate receptors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-08-05 | — | — | US | disclosed |
| US-8778923-B2 | GLP-1 receptor modulators | RECEPTOS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140187554-A1 | MODULATORS OF THE NUCLEAR HORMONE RECEPTOR ROR | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140170742-A1 | MULTILAYERED STRUCTURE INCLUDING CYCLIC OLEFIN POLYMER OR COPOLYMER, AND PHOTOBIOREACTOR INCLUDING THE SAME | RAVEN INDUSTRIES, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140142029-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| EP-2727909-A1 | Inhibitors of focal adhesion kinase | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-05-07 | — | — | EP | disclosed |
| EP-2134689-B1 | INHIBITORS OF FOCAL ADHESION KINASE | SCRIPPS RESEARCH INST (US) | 2014-04-23 | — | — | EP | disclosed |
| EP-2706999-A2 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | Receptos, Inc. (US) | 2014-03-19 | — | — | EP | disclosed |
| US-20140039183-A1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | RECEPTOS LLC | 2014-02-06 | — | — | US | disclosed |
| US-20140031290-A1 | NOVEL GLP-1 RECEPTOR STABILIZERS AND MODULATORS | RECEPTOS LLC | 2014-01-30 | — | — | US | disclosed |
| US-20140031371-A1 | POLY AROMATIC SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140024661-A1 | FUSED PYRIMIDINES AND SUBSTITUTED QUINAZOLINES AS INHIBITORS OF P97 | CLEAVE BIOSCIENCES, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| WO-2014015291-A1 | FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX | ZHOU HAN-JIE (US) | 2014-01-23 | — | — | WO | disclosed |
| US-20130338196-A1 | ALPHA-KETOHETEROCYCLES AND METHODS OF MAKING AND USING | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-12-19 | — | — | US | disclosed |
| US-20130324559-A1 | DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES | PARION SCIENCES, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| US-8592451-B2 | Reversible nondepolarizing neuromuscular blockade agents and methods for their use | CORNELL UNIVERSITY (US) | 2013-11-26 | — | — | US | disclosed |
| US-8586614-B2 | Urea glucokinase activators | NOVO NORDISK A/S (DK) | 2013-11-19 | — | — | US | disclosed |
| US-8575144-B2 | Beta-lactamase inhibitory compounds | SOUTHERN METHODIST UNIVERSITY (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575176-B2 | Heteroaromatic pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20130281360-A1 | BROAD SPECTRUM ANTIBIOTIC ARYLOMYCIN ANALOGS | THE SCIPPS RESEARCH INSTITUTE (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130281453-A1 | ANTI-CANCER SERINE HYDROLASE INHIBITORY CARBAMATES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130281443-A1 | INHIBITORS OF FOCAL ADHESION KINASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130236532-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISEASES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2013-09-12 | — | — | US | disclosed |
| EP-2635280-A2 | CYTOSINE DEAMINASE MODULATORS FOR ENHANCEMENT OF DNA TRANSFECTION | Regents of the University of Minnesota (US) | 2013-09-11 | — | — | EP | disclosed |
| US-8530503-B2 | Modulators of sphingosine phosphate receptors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-09-10 | — | — | US | disclosed |
| US-20130231326-A1 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | RECEPTOS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130217619-A1 | LINEAR PEPTIDE ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130217706-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130210053-A1 | MECHANOCHROMIC LUMINESCENT DIFLUOROBORON BETA-DIKETONATES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2013-08-15 | — | — | US | disclosed |
| US-8507538-B2 | Selective heterocyclic sphingosine 1 phosphate receptor modulators | RECEPTOS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8501763-B2 | Inhibitors of focal adhesion kinase | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501982-B2 | GLP-1 receptor stabilizers and modulators | RECEPTOS, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20130196966-A1 | SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | RECEPTOS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-8486892-B2 | Blood coagulation factor inhibitors | NOVO NORDISK HEALTH CARE AG (CH) | 2013-07-16 | — | — | US | disclosed |
| US-20130178420-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-8481573-B2 | Modulators of sphingosine phosphate receptors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-07-09 | — | — | US | disclosed |
| US-8466183-B2 | Modulators of sphingosine phosphate receptors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-06-18 | — | — | US | disclosed |
| US-20130137821-A1 | AMPHIPHILIC MULTI-ARM COPOLYMERS AND NANOMATERIALS DERIVED THEREFROM | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| WO-2013074059-A2 | CYTOSINE DEAMINASE MODULATORS FOR ENHANCEMENT OF DNA TRANSFECTION | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2013-05-23 | — | — | WO | disclosed |
| US-8445577-B2 | Amphiphilic multi-arm copolymers and nanomaterials derived therefrom | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| EP-1904467-B1 | Urea glucokinase activators | NOVO NORDISK AS (DK) | 2013-05-01 | — | — | EP | disclosed |
| EP-2579888-A2 | NOVEL GLP-1 RECEPTOR STABILIZERS AND MODULATORS | Receptos, Inc. (US) | 2013-04-17 | — | — | EP | disclosed |
| US-8415295-B2 | Heterocyclic boronic acid compounds | PHENOMIX CORPORATION (US) | 2013-04-09 | — | — | US | disclosed |
| US-20130079318-A1 | BETA-LACTAMASE INHIBITORY COMPOUNDS | SOUTHERN METHODIST UNIVERSITY (US) | 2013-03-28 | — | — | US | disclosed |
| US-20130030120-A1 | AMPHIPHILIC MULTI-ARM COPOLYMERS AND NANOMATERIALS DERIVED THEREFROM | AIR FORCE, UNITED STATES | 2013-01-31 | — | — | US | disclosed |
| US-8362048-B2 | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | RECEPTOS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8357706-B2 | Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | RECEPTOS, INC. (US) | 2013-01-22 | — | — | US | disclosed |
| US-20130018040-A1 | Compositions And Methods For Treating Toxoplasmosis, Cryptosporidiosis, And Other Apicomplexan Protozoan Related Diseases | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2013-01-17 | — | — | US | disclosed |
| US-20120329840-A1 | NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-12-27 | — | — | US | disclosed |
| US-20120329838-A1 | NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-12-27 | — | — | US | disclosed |
| US-20120329839-A1 | NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-12-27 | — | — | US | disclosed |
| US-20120309757-A1 | N-BIPHENYLMETHYLINDOLE MODULATORS OF PPARG | SCRIPPS RESEARCH INSTITUTE, THE (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120309769-A1 | N-BENZYLINDOLE MODULATORS OF PPARG | SCRIPPS RESEARCH INSTITUTE, THE (US) | 2012-12-06 | — | — | US | disclosed |
| WO-2012158550-A2 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | RECEPTOS, INC. (US) | 2012-11-22 | — | — | WO | disclosed |
| EP-1723128-B1 | HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS | NOVO NORDISK AS (DK) | 2012-11-07 | — | — | EP | disclosed |
| US-8299051-B2 | Beta-lactamase inhibitory compounds | SOUTHERN METHODIST UNIVERSITY (US) | 2012-10-30 | — | — | US | disclosed |
| US-8288391-B2 | Epithelial Sodium Channel and Acid Sensitive Ion Channel modulators; blocking or enhancing salt and sour tastes; additives in chocolate, ice cream, beverages, candies, or pet foods; side effect reduction | PARION SCIENCES, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8263634-B2 | Heteroaryl-ureas and their use as glucokinase activators | NOVO NORDISK A/S (DK) | 2012-09-11 | — | — | US | disclosed |
| EP-2471533-A1 | Aryl carbonyl derivatives as therapeutic agents | Novo Nordisk A/S (DK) | 2012-07-04 | — | — | EP | disclosed |
| US-20120116083-A1 | HETEROAROMATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| EP-2444397-A1 | Heteroaryl-ureas and their use as glucokinase activators | Novo Nordisk A/S (DK) | 2012-04-25 | — | — | EP | disclosed |
| US-20120095041-A1 | REVERSIBLE NONDEPOLARIZING NEUROMUSCULAR BLOCKADE AGENTS AND METHODS FOR THEIR USE | CORNELL UNIVERSITY (US) | 2012-04-19 | — | — | US | disclosed |
| US-8148413-B2 | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes | TRANSTECH PHARMA, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148412-B2 | e.g. {-[3-Cyclopentyl-2-(4-methane sulfonyl-phenyl)-propionylamino]-5-methyl-thiazol-4-yl}-acetic acid ethyl ester; antidiabetic and hypoglycemic agent; non-insulin dependent diabetis, obesity, impaired glucose tolerance, eating disorder, dyslipidemia, hyperlipidemia, hypertension | NOVO NORDISK A/S (DK) | 2012-04-03 | — | — | US | disclosed |
| EP-1904438-B1 | DICYCLOALKYLCARBAMOYL UREAS AS GLUCOKINASE ACTIVATORS | NOVO NORDISK AS (DK) | 2012-02-29 | — | — | EP | disclosed |
| US-8124607-B2 | Poly aromatic pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| WO-2011156655-A2 | NOVEL GLP-1 RECEPTOR STABILIZERS AND MODULATORS | RECEPTOS, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
| US-20110306542-A1 | NOVEL GLP-1 RECEPTOR STABILIZERS AND MODULATORS | RECEPTOS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110301158-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | NOVO NORDISK A/S (DK) | 2011-12-08 | — | — | US | disclosed |
| US-8063081-B2 | N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase | NOVO NORDISK A/S (DK) | 2011-11-22 | — | — | US | disclosed |
| EP-2377856-A1 | Urea glucokinase activators | NOVO NORDISK A/S (DK) | 2011-10-19 | — | — | EP | disclosed |
| US-20110229453-A1 | BLOOD COAGULATION FACTOR INHIBITORS | NOVO NORDISK HEALTH CARE AG (CH) | 2011-09-22 | — | — | US | disclosed |
| US-8022066-B2 | 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-09-20 | — | — | US | disclosed |
| EP-2097388-B1 | NOVEL 2-(2-HYDROXYPHENYL)BENZIMIDAZOLES USEFUL FOR TREATING OBESITY AND DIABETES | HIGH POINT PHARMACEUTICALS LLC (US) | 2011-09-07 | — | — | EP | disclosed |
| US-7999114-B2 | Dicycloalkylcarbamoyl ureas as glucokinase activators | NOVO NORDISK A/S (DK) | 2011-08-16 | — | — | US | disclosed |
| US-20110183953-A1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | RECEPTOS LLC | 2011-07-28 | — | — | US | disclosed |
| US-20110178056-A1 | SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | RECEPTOS LLC | 2011-07-21 | — | — | US | disclosed |
| US-20110172202-A1 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | RECEPTOS LLC | 2011-07-14 | — | — | US | disclosed |
| US-20110150833-A1 | BENZOPYRANS AND ANALOGS AS RHO KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110144017-A1 | Protein conjugates and methods for their preparation | NOVO NORDISK HEALTH CARE AG (CH) | 2011-06-16 | — | — | US | disclosed |
| US-20110130402-A1 | HETEROAROMATIC GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2011-06-02 | — | — | US | disclosed |
| US-20110124634-A1 | BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES | PONIARD PHARMACEUTICALS, INC. | 2011-05-26 | — | — | US | disclosed |
| US-7939690-B2 | Haloalkylsulfone substituted compounds useful for treating obesity and diabetes | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-05-10 | — | — | US | disclosed |
| US-20110098241-A1 | RAPAMYCIN ANALOGS AS ANTI-CANCER AGENTS | PONIARD PHARMACEUTICALS, INC. | 2011-04-28 | — | — | US | disclosed |
| US-20110082144-A1 | N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES | TRANSTECH PHARMA, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| EP-2305648-A1 | Amide derivatives useful as glucokinase activators | Novo Nordisk A/S (DK) | 2011-04-06 | — | — | EP | disclosed |
| US-20110077234-A1 | Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2011-03-31 | — | — | US | disclosed |
| US-7915299-B2 | 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-03-29 | — | — | US | disclosed |
| US-20110060019-A1 | HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2011-03-10 | — | — | US | disclosed |
| EP-2291080-A1 | NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS | The Scripps Research Institute (US) | 2011-03-09 | — | — | EP | disclosed |
| US-20110052562-A1 | BENZIMIDAZOLES AND ANALOGS AS RHO KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110053958-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-7897628-B2 | {2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase | NOVO NORDISK A/S (DK) | 2011-03-01 | — | — | US | disclosed |
| US-7897788-B2 | Indol-1-yl-acetic acid derivatives | ACTELION PHARMACEUTICAL LTD. (CH) | 2011-03-01 | — | — | US | disclosed |
| US-20110046121-A1 | INHIBITORS OF FOCAL ADHESION KINASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110038835-A1 | ANILIDES AND ANALOGS AS RHO KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-02-17 | — | — | US | disclosed |
| US-7884210-B2 | {2-[3-(2-Cyclohex-1-enyl-ethyl)-3-(trans-4-methyl-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid; for treatment of type 2 diabetes | NOVO NORDISK A/S (DK) | 2011-02-08 | — | — | US | disclosed |
| US-20110021538-A1 | PROCESSES FOR THE PREPARATION OF PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR | ARENA PHARMACEUTICALS, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-7872139-B2 | e.g.1,1-Dicyclohexyl-3-[5-(pyridin-2-ylsulfanyl)-thiazol-2-yl]-urea; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial, in particular, type 2 diabetes | NOVO NORDISK A/S (DK) | 2011-01-18 | — | — | US | disclosed |
| US-7872052-B2 | Use of heterocyclic compounds as SCCE inhibitors | AREXIS AB (SE) | 2011-01-18 | — | — | US | disclosed |
| US-20110003752-A1 | New Blood Coagulation Factor Inhibitors | NOVO NORDISK HEALTH CARE A/G (CH) | 2011-01-06 | — | — | US | disclosed |
| US-20100323953-A1 | MACROCYCLIC HEPATITIS C PROTEASE INHIBITORS | PHENOMIX CORPORATION (US) | 2010-12-23 | — | — | US | disclosed |
| US-7851636-B2 | {2-[3-Cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial; antidiabetic agents | NOVO NORDISK A/S (DK) | 2010-12-14 | — | — | US | disclosed |
| US-7825139-B2 | Compounds and methods for selective inhibition of dipeptidyl peptidase-IV | Forest Laboratories Holdings Limited (BM) | 2010-11-02 | — | — | US | disclosed |
| US-7812043-B2 | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes | TRANSTECH PHARMA, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-20100249161-A1 | 2- ( 2 -HYDROXYPHENYL) -QUINAZOLIN-4-ONES USEFUL FOR TREATING OBESITY AND DIABETES | HIGH POINT PHARMACEUTICALS, LLC | 2010-09-30 | — | — | US | disclosed |
| US-7786163-B2 | Constrained cyano compounds | Forest Laboratories Holdings Limited (BM) | 2010-08-31 | — | — | US | disclosed |
| US-20100204288-A1 | {2-[3-Cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial; antidiabetic agents | NOVO NORDISK A/S (DK) | 2010-08-12 | — | — | US | disclosed |
| EP-1740171-B1 | INDOL-1-YL-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-06-09 | — | — | EP | disclosed |
| EP-1575575-B1 | SAFE CHEMICAL UNCOUPLERS FOR THE TREATMENT OF OBESITY | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-05-19 | — | — | EP | disclosed |
| US-20100120716-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | PHENOMIX CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120661-A1 | HETEROCYCLIC BORONIC ACID COMPOUNDS | PHENOMIX CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100113536-A1 | HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | HIGH POINT PHARMACEUTICALS, LLC | 2010-05-06 | — | — | US | disclosed |
| WO-2009151529-A9 | NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-04-08 | — | — | WO | disclosed |
| US-20100075932-A1 | NOVEL SALICYLIC ANILIDES | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100063122-A1 | NOVEL 2-(2-HYDROXYPHENYL)BENZIMlDAZOLES USEFUL FOR TREATING OBESITY AND DIABETES | HIGH POINT PHARMACEUTICALS, LLC | 2010-03-11 | — | — | US | disclosed |
| US-7674913-B2 | Heterocyclic boronic acid compounds | PHENOMIX CORPORATION (US) | 2010-03-09 | — | — | US | disclosed |
| EP-1631295-B1 | USE OF CONDENSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN DISEASES | AREXIS AB (SE) | 2010-03-03 | — | — | EP | disclosed |
| US-20100041657-A1 | HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDICK A/S (DK) | 2010-02-18 | — | — | US | disclosed |
| US-20100010001-A1 | NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-01-14 | — | — | US | disclosed |
| US-20100009954-A1 | BETA-LACTAMASE INHIBITORY COMPOUNDS | SOUTHERN METHODIST UNIVERSITY | 2010-01-14 | — | — | US | disclosed |
| US-7645791-B2 | Salicylic anilides | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-01-12 | — | — | US | disclosed |
| US-20090325889-A1 | HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | CAMPBELL DAVID ALAN | 2009-12-31 | — | — | US | disclosed |
| US-20090325941-A1 | NOVEL 2-(2-HYDROXYPHENYL) BENZOTHIADIAZINES USEFUL FOR TREATING OBESITY AND DIABETES | HIGH POINT PHARMACEUTICALS, LLC | 2009-12-31 | — | — | US | disclosed |
| EP-2134689-A2 | INHIBITORS OF FOCAL ADHESION KINASE | The Scripps Research Institute (US) | 2009-12-23 | — | — | EP | disclosed |
| WO-2009151529-A1 | NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20090304631-A1 | HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | PHENOMIX CORPORATION | 2009-12-10 | — | — | US | disclosed |
| US-7598391-B2 | Heteroaryl-ureas and their use as glucokinase activators | NOVO NORDISK A/S (DK) | 2009-10-06 | — | — | US | disclosed |
| EP-2097380-A1 | NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | High Point Pharmaceuticals, LLC (US) | 2009-09-09 | — | — | EP | disclosed |
| EP-2097391-A1 | 2- ( 2 -HYDROXYPHENYL) -QUINAZOLIN-4-ONES USEFUL FOR TREATING OBESITY AND DIABETES | High Point Pharmaceuticals, LLC (US) | 2009-09-09 | — | — | EP | disclosed |
| EP-2097388-A1 | NOVEL 2-(2-HYDROXYPHENYL)BENZIMIDAZOLES USEFUL FOR TREATING OBESITY AND DIABETES | High Point Pharmaceuticals, LLC (US) | 2009-09-09 | — | — | EP | disclosed |
| EP-2096104-A1 | Organic diamines as mGluR7 modulators | Novartis AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| US-7582769-B2 | Dicycloalkyl urea glucokinase activators | NOVO NORDISK A/S (DK) | 2009-09-01 | — | — | US | disclosed |
| US-20090216013-A1 | e.g.1,1-Dicyclohexyl-3-[5-(pyridin-2-ylsulfanyl)-thiazol-2-yl]-urea; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial, in particular, type 2 diabetes | NOVO NORDISK A/S (DK) | 2009-08-27 | — | — | US | disclosed |
| US-20090214444-A1 | POLY AROMATIC SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-7576121-B2 | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV | PHENOMIX CORPORATION (US) | 2009-08-18 | — | — | US | disclosed |
| EP-2086951-A1 | NOVEL 2-(2-HYDROXYPHENYL) BENZOTHIADIAZINES USEFUL FOR TREATING OBESITY AND DIABETES | High Point Pharmaceuticals, LLC (US) | 2009-08-12 | — | — | EP | disclosed |
| EP-1625112-B1 | NOVEL COMPOUNDS FOR TREATMENT OF OBESITY | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-07-22 | — | — | EP | disclosed |
| US-7541373-B2 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2009-06-02 | — | — | US | disclosed |
| US-20090118501-A1 | Dicycloalkyl Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2009-05-07 | — | — | US | disclosed |
| US-20090105482-A1 | Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| US-20090062396-A1 | Novel Haloalkoxy-Substituted Salicylic Anilides | NOVO NORDISK A/S (DK) | 2009-03-05 | — | — | US | disclosed |
| US-20090005434-A1 | Novel Salicylic Anilides | NOVO NORDISK A/S (DK) | 2009-01-01 | — | — | US | disclosed |
| US-20080319028-A1 | Dicycloalkylcarbamoyl Ureas As Glucokinase Activators | NOVO NORDISK A/S (DK) | 2008-12-25 | — | — | US | disclosed |
| WO-2008150446-A1 | INHIBITORS OF PROTEIN KINASES | LIANG CONGXIN (US) | 2008-12-11 | — | — | WO | disclosed |
| EP-1997533-A1 | Heterocyclic boronic acid compounds, dipeptidyl peptidase IV inhibitors | Phenomix Corporation (US) | 2008-12-03 | — | — | EP | disclosed |
| US-20080293740-A1 | METHOD OF TREATING ACID-SENSING ION CHANNEL MEDIATED PAIN, COUGH SUPPRESSION, AND CENTRAL NERVOUS SYSTEM DISORDERS | PARION SCIENCES, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080255240-A1 | Sulfonamide Derivatives | NOVO NORDISK A/S (DK) | 2008-10-16 | — | — | US | disclosed |
| US-20080249109-A1 | PYRAZINOYLGUANIDINE COMPOUNDS FOR USE AS TASTE MODULATORS | PARION SCIENCES, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080242698-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| EP-1496877-B1 | METHOD AND COMPOSITION FOR TREATMENT OF DIABETES, HYPERTENSION, CHRONIC HEART FAILURE AND FLUID RETENTIVE STATES | NOVO NORDISK AS (DK) | 2008-10-01 | — | — | EP | disclosed |
| US-20080234381-A1 | Novel Trifluoromethoxy-Substituted Aryl Anilides | NOVO NORDISK A/S (DK) | 2008-09-25 | — | — | US | disclosed |
| WO-2008115369-A2 | INHIBITORS OF FOCAL ADHESION KINASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-09-25 | — | — | WO | disclosed |
| EP-1967522-A1 | New blood coagulation factor inhibitors | NOVO NORDISK A/S (DK) | 2008-09-10 | — | — | EP | disclosed |
| US-20080139562-A1 | Heteroaromatic Glucokinase Activators | NOVO NORDISK A/S (DK) | 2008-06-12 | — | — | US | disclosed |
| US-7384967-B2 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2008-06-10 | — | — | US | disclosed |
| EP-1924551-A2 | ORGANIC COMPOUNDS | Novartis Pharma AG (CH) | 2008-05-28 | — | — | EP | disclosed |
| WO-2008059023-A1 | NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | HIGH POINT PHARMACEUTICALS, LLC (US) | 2008-05-22 | — | — | WO | disclosed |
| US-20080119454-A1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2008-05-22 | — | — | US | disclosed |
| US-20080119455-A1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2008-05-22 | — | — | US | disclosed |
| WO-2008059026-A1 | NOVEL 2-(2-HYDROXYPHENYL)BENZIMIDAZOLES USEFUL FOR TREATING OBESITY AND DIABETES | HIGH POINT PHARMACEUTICALS, LLC (US) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008059025-A1 | NOVEL 2-(2-HYDROXYPHENYL) BENZOTHIADIAZINES USEFUL FOR TREATING OBESITY AND DIABETES | HIGH POINT PHARMACEUTICALS, LLC (US) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008059024-A1 | 2- ( 2 -HYDROXYPHENYL) -QUINAZOLIN-4-ONES USEFUL FOR TREATING OBESITY AND DIABETES | HIGH POINT PHARMACEUTICALS, LLC (US) | 2008-05-22 | — | — | WO | disclosed |
| US-20080113944-A1 | Novel Indole Derivatives | NOVO NORDISK A/S (DK) | 2008-05-15 | — | — | US | disclosed |
| EP-1904466-A1 | DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS | Novo Nordisk A/S (DK) | 2008-04-02 | — | — | EP | disclosed |
| EP-1904438-A1 | DICYCLOALKYLCARBAMOYL UREAS AS GLUCOKINASE ACTIVATORS | Novo Nordisk A/S (DK) | 2008-04-02 | — | — | EP | disclosed |
| EP-1904467-A1 | UREA GLUCOKINASE ACTIVATORS | Novo Nordisk A/S (DK) | 2008-04-02 | — | — | EP | disclosed |
| EP-1404675-B1 | DPP-IV-INHIBITING PURINE DERIVATIVES FOR THE TREATMENT OF DIABETES | NOVO NORDISK AS (DK) | 2008-03-12 | — | — | EP | disclosed |
| EP-1888513-A1 | NOVEL TRIFLUOROMETHOXY-SUBSTITUTED ARYL ANILIDES | NOVO NORDISK A/S (DK) | 2008-02-20 | — | — | EP | disclosed |
| EP-1888508-A2 | NOVEL HALOALKOXY-SUBSTITUTED SALICYLIC ANILIDES | NOVO NORDISK A/S (DK) | 2008-02-20 | — | — | EP | disclosed |
| EP-1881961-A1 | NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDISK A/S (DK) | 2008-01-30 | — | — | EP | disclosed |
| US-20080007158-A1 | Linear Polysiloxanes, Silicone Composition, and Organic Light-Emitting Diode | FAROOQ OMAR | 2008-01-10 | — | — | US | disclosed |
| US-20070213519-A1 | Building Block Forming A C=C Double Bond Upon Reaction | NUEVOLUTION A/S (DK) | 2007-09-13 | — | — | US | disclosed |
| US-20070208004-A1 | Indol-1-yl-acetic acid derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-09-06 | — | — | US | disclosed |
| EP-1824835-A1 | HETEROAROMATIC GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-08-29 | — | — | EP | disclosed |
| US-20070197552-A1 | Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states | NOVO NORDISK A/S (DK) | 2007-08-23 | — | — | US | disclosed |
| US-20070185128-A1 | Compounds and compositions for treating obesity | NOVO NORDISK A/S (DK) | 2007-08-09 | — | — | US | disclosed |
| US-7235538-B2 | Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV | NOVO NORDISK A/S (DK) | 2007-06-26 | — | — | US | disclosed |
| US-7192952-B2 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV | NOVO NORDISK, A/S (DK) | 2007-03-20 | — | — | US | disclosed |
| US-20070060547-A1 | (2R)-1-{2-[(3R)-pyrrolidin-3-ylamino]-acetyl}-pyrrolidine-2-boronic acid; Dipeptidyl peptidase IV (DPP-IV) inhibitors; diabetes, hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis | PHENOMIX CORPORATION | 2007-03-15 | — | — | US | disclosed |
| WO-2007025709-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-03-08 | — | — | WO | disclosed |
| US-20070054897-A1 | 1,1-Dicyclohexyl-3-thiazol-2-yl-urea, 3-(5-Chloro-thiazol-2-yl)-1,1-dicyclohexyl-urea, for example; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial, in particular, type 2 diabetes | NOVO NORDISK A/S (DK) | 2007-03-08 | — | — | US | disclosed |
| EP-1758856-A2 | INDOLE DERIVATIVES FOR THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2007-03-07 | — | — | EP | disclosed |
| EP-1756025-A1 | SULFONAMIDE DERIVATIVES | NOVO NORDISK A/S (DK) | 2007-02-28 | — | — | EP | disclosed |
| US-20070027140-A1 | N-heteroaryl indole carboxamides and analogues thereof, for use as glcokinase activators in the treatment of diabetes | NOVO NORDISK A/S (DK) | 2007-02-01 | — | — | US | disclosed |
| WO-2007006761-A1 | DICYCLOALKYLCARBAMOYL UREAS AS GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007006760-A1 | DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007006814-A1 | UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-01-18 | — | — | WO | disclosed |
| US-20070010559-A1 | Indole derivatives for use as chemical uncoupler | NOVO NORDISK A/S (DK) | 2007-01-11 | — | — | US | disclosed |
| US-20070004799-A1 | Novel compounds for the treatment of obesity | NOVO NORDISK A/S (DK) | 2007-01-04 | — | — | US | disclosed |
| US-20070004794-A1 | Novel salicylic anilides | NOVO NORDISK A/S (DK) | 2007-01-04 | — | — | US | disclosed |
| US-20060276410-A1 | COMPOUNDS AND METHODS FOR SELECTIVE INHIBITION OF DIPEPTIDYL PEPTIDASE-IV | Forest Laboratories Holding Limited (BM) | 2006-12-07 | — | — | US | disclosed |
| WO-2006125781-A2 | HALOALKOXY-SUBSTITUTED SALICYLIC ANILIDES | NOVO NORDISK A/S (DK) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006125778-A1 | NOVEL TRIFLUOROMETHOXY-SUBSTITUTED ARYL ANILIDES | NOVO NORDISK A/S (DK) | 2006-11-30 | — | — | WO | disclosed |
| EP-1723128-A1 | HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2006-11-22 | — | — | EP | disclosed |
| WO-2006120178-A1 | NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDISK A/S (DK) | 2006-11-16 | — | — | WO | disclosed |
| US-20060258651-A1 | Use of heterocyclic compounds as scce inhibitors | QUANTUM LTO HOLDINGS, LLC | 2006-11-16 | — | — | US | disclosed |
| US-20060258621-A1 | PYRROLIDINE COMPOUNDS AND METHODS FOR SELECTIVE INHIBITION OF DIPEPTIDYL PEPTIDASE-IV | SINO-MED INTERNATIONAL ALLIANCE, INC. | 2006-11-16 | — | — | US | disclosed |
| US-7115624-B1 | Method of inhibiting protein tyrosine phosphatase 1B and/or T-cell protein tyrosine phosphatase 4 and/or other PTPases with an Asp residue at position 48 | NOVO NORDISK A/S (DK) | 2006-10-03 | — | — | US | disclosed |
| US-20060183783-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2006-08-17 | — | — | US | disclosed |
| EP-1689700-A1 | NOVEL SALICYLIC ANILIDES | NOVO NORDISK A/S (DK) | 2006-08-16 | — | — | EP | disclosed |
| EP-1689392-A1 | N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2006-08-16 | — | — | EP | disclosed |
| EP-1689707-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2006-08-16 | — | — | EP | disclosed |
| EP-1689710-A1 | INDOLE DERIVATIVES FOR USE AS CHEMICAL UNCOUPLER | NOVO NORDISK A/S (DK) | 2006-08-16 | — | — | EP | disclosed |
| US-20060166197-A1 | Building block capable of transferring a functional entity | GOULIAEV ALEX H | 2006-07-27 | — | — | US | disclosed |
| US-20060160741-A1 | Dimeric TF antagonists | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | disclosed |
| US-20060128662-A1 | Novel compounds for treatment of obesity | NOVO NORDISK A/S (DK) | 2006-06-15 | — | — | US | disclosed |
| EP-1214324-B1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK AS (DK) | 2006-06-14 | — | — | EP | disclosed |
| WO-2006058923-A1 | HETEROAROMATIC GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2006-06-08 | — | — | WO | disclosed |
| US-7019026-B1 | Modulators of Protein Tyrosine Phosphatases (PTPases) | NOVO NORDISK A/S (DK) | 2006-03-28 | — | — | US | disclosed |
| US-20060035884-A1 | N-cyclic sulfonamido inhibitors of gamma secretase | ELAN PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | US | disclosed |
| EP-1625112-A1 | NOVEL COMPOUNDS FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2006-02-15 | — | — | EP | disclosed |
| US-20060024730-A1 | TF binding compounds | NOVO NORDISK A/S (DK) | 2006-02-02 | — | — | US | disclosed |
| US-20060018831-A1 | TF binding agent and use thereof | NOVO NORDISK A/S (DK) | 2006-01-26 | — | — | US | disclosed |
| US-20060009518-A1 | Constrained cyano compounds | Forest Laboratories Holding Limited (BM) | 2006-01-12 | — | — | US | disclosed |
| US-20050288347-A1 | Certain triazole-based compounds, compositions, and uses thereof | AGRIUS GROUP, LLC. | 2005-12-29 | — | — | US | disclosed |
| WO-2005105785-A2 | INDOLE DERIVATIVES FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2005-11-10 | — | — | WO | disclosed |
| US-20050247001-A1 | Building block forming a c-c or a c-hetero atom bond uponreaction | NUEVOLUTION A/S (DK) | 2005-11-10 | — | — | US | disclosed |
| WO-2005105712-A1 | SULFONAMIDE DERIVATIVES | NOVO NORDISK A/S (DK) | 2005-11-10 | — | — | WO | disclosed |
| EP-1214325-B1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK AS (DK) | 2005-11-09 | — | — | EP | disclosed |
| EP-1080095-B1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK AS (DK) | 2005-11-02 | — | — | EP | disclosed |
| EP-1587549-A2 | RADIOLABELLED TISSUE FACTOR BINDING AGENT AND THE USE THEREOF | NOVO NORDISK A/S (DK) | 2005-10-26 | — | — | EP | disclosed |
| US-20050221318-A1 | Building block forming a c-c bond upon reaction | NUEVOLUTION A/S (DK) | 2005-10-06 | — | — | US | disclosed |
| US-6951878-B2 | Benzo[b]thiophenyl or tetrahydro-benzo[b]thiophenyl modulators of protein tyrosine phosphatases (PTPases) | NOVO NORDISK A/S (DK) | 2005-10-04 | — | — | US | disclosed |
| EP-1575575-A2 | SAFE CHEMICAL UNCOUPLERS FOR THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2005-09-21 | — | — | EP | disclosed |
| EP-1572669-A2 | 2,5-DIKETOPIPERAZINES FOR THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2005-09-14 | — | — | EP | disclosed |
| US-20050176948-A1 | Building block capable of functional entity transfer to nucleophil | NUEVOLUTION A/S (DK) | 2005-08-11 | — | — | US | disclosed |
| EP-1561752-A1 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV | NOVO NORDISK A/S (DK) | 2005-08-10 | — | — | EP | disclosed |
| EP-1558245-A2 | USE OF GLYCOGEN PHOSPHORYLASE INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISEASES | NOVO NORDISK A/S (DK) | 2005-08-03 | — | — | EP | disclosed |
| WO-2005066145-A1 | HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2005-07-21 | — | — | WO | disclosed |
| US-20050148606-A1 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV | KANSTRUP ANDERS B (DK) | 2005-07-07 | — | — | US | disclosed |
| EP-1301187-B1 | PURINE-2,6-DIONES WHICH ARE INHIBITORS OF THE ENZYME DIPEPTIDYL PEPTIDASE IV (DPP-IV) | NOVO NORDISK AS (DK) | 2005-07-06 | — | — | EP | disclosed |
| US-20050143578-A1 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION | 2005-06-30 | — | — | US | disclosed |
| US-6908926-B1 | Substituted imidazoles, their preparation and use | NOVO NORDISK A/S (DK) | 2005-06-21 | — | — | US | disclosed |
| WO-2005051908-A1 | INDOLE DERIVATIVES FOR USE AS CHEMICAL UNCOUPLER | NOVO NORDISK A/S (DK) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005051900-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005051894-A1 | NOVEL SALICYLIC ANILIDES | NOVO NORDISK A/S (DK) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005049019-A1 | N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2005-06-02 | — | — | WO | disclosed |
| US-20050119332-A1 | Substituted thiophene compounds as modulators of protein tyrosine phosphatases (PTPases) | JEPPESEN LONE (DK) | 2005-06-02 | — | — | US | disclosed |
| EP-1532980-A1 | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes | NOVO NORDISK A/S (DK) | 2005-05-25 | — | — | EP | disclosed |
| EP-1531815-A1 | GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2005-05-25 | — | — | EP | disclosed |
| US-6869947-B2 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV | NOVO NORDISK A/S (DK) | 2005-03-22 | — | — | US | disclosed |
| US-20050054618-A1 | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases | RYTVED KLAUS ASGER (DK) | 2005-03-10 | — | — | US | disclosed |
| EP-1496877-A2 | METHOD AND COMPOSITION FOR TREATMENT OF DIABETES, HYPERTENSION, CHRONIC HEART FAILURE AND FLUID RETENTIVE STATES | NOVO NORDISK A/S (DK) | 2005-01-19 | — | — | EP | disclosed |
| EP-1490384-A2 | A BUILDING BLOCK FORMING A C-C BOND UPON REACTION | Nuevolution A/S (DK) | 2004-12-29 | — | — | EP | disclosed |
| EP-1487851-A2 | A BUILDING BLOCK CAPABLE OF FUNCTIONAL ENTITY TRANSFER TO NUCLEOPHIL | Nuevolution A/S (DK) | 2004-12-22 | — | — | EP | disclosed |
| EP-1487849-A2 | A BUILDING BLOCK CAPABLE OF TRANSFERRING A FUNCTIONAL ENTITY | Nuevolution A/S (DK) | 2004-12-22 | — | — | EP | disclosed |
| EP-1487850-A2 | A BUILDING BLOCK FORMING A C-C OR A C-HETERO ATOM BOND UPON REACTION | Nuevolution A/S (DK) | 2004-12-22 | — | — | EP | disclosed |
| EP-1487848-A2 | A BUILDING BLOCK FORMING A C=C DOUBLE BOND UPON REACTION | Nuevolution A/S (DK) | 2004-12-22 | — | — | EP | disclosed |
| EP-1485476-A2 | DIMERIC TF ANTAGONIST | NOVO NORDISK A/S (DK) | 2004-12-15 | — | — | EP | disclosed |
| WO-2004101505-A1 | NOVEL COMPOUNDS FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004099127-A1 | NOVEL COMPOUNDS AS KINASE INHIBITORS | NOVO NORDISK A/S (DK) | 2004-11-18 | — | — | WO | disclosed |
| EP-1463727-A2 | HETEROCYCLIC COMPOUNDS THAT ARE INHIBITORS OF THE ENZYME DPP-IV | NOVO NORDISK A/S (DK) | 2004-10-06 | — | — | EP | disclosed |
| EP-1458382-A1 | AMIDE DERIVATIVES AS GK ACTIVATORS | NOVO NORDISK A/S (DK) | 2004-09-22 | — | — | EP | disclosed |
| WO-2004064870-A2 | RADIOLABELLED TISSUE FACTOR BINDING AGENT AND THE USE THEREOF | NOVO NORDISK A/S (DK) | 2004-08-05 | — | — | WO | disclosed |
| US-20040138301-A1 | Chemical uncouplers for the treatment of obesity | HIGH POINT PHARMACEUTICALS, LLC | 2004-07-15 | — | — | US | disclosed |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-06-24 | — | — | US | disclosed |
| WO-2004048345-A2 | 2,5-DIKETOPIPERAZINES FOR THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2004-06-10 | — | — | WO | disclosed |
| US-20040110929-A1 | TF binding compound | NOVO NORDISK A/S (DK) | 2004-06-10 | — | — | US | disclosed |
| WO-2004041256-A2 | SAFE CHEMICAL UNCOUPLERS FOR THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2004-05-21 | — | — | WO | disclosed |
| WO-2004037233-A2 | USE OF GLYCOGEN PHOSPHORYLASE INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISEASES | NOVO NORDISK A/S (DK) | 2004-05-06 | — | — | WO | disclosed |
| US-20040082641-A1 | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases | NOVO NORDISK A/S (DK) | 2004-04-29 | — | — | US | disclosed |
| WO-2004033455-A2 | HEMISUCCINATE SALTS OF HETEROCYCLIC DPP-IV INHIBITORS | NOVO NORDISK A/S (DK) | 2004-04-22 | — | — | WO | disclosed |
| US-20040072755-A1 | TF antagonist | STENNICKE HENNING RALF (DK) | 2004-04-15 | — | — | US | disclosed |
| US-20040034014-A1 | Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV | KANSTRUP ANDERS BENDTZ (DK) | 2004-02-19 | — | — | US | disclosed |
| WO-2004007557-A2 | TF ANTAGONIST | NOVO NORDISK A/S (DK) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004002481-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | NOVO NORDISK A/S (DK) | 2004-01-08 | — | — | WO | disclosed |
| US-20030236272-A1 | Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states | NOVO NORDISK A/S (DK) | 2003-12-25 | — | — | US | disclosed |
| US-20030229018-A1 | Dimeric TF antagonist | NOVO NORDISK A/S (DK) | 2003-12-11 | — | — | US | disclosed |
| US-6645995-B2 | Dipeptidyl peptidase-IV (DPP-IV); treating type II diabetes in a human; amino acid amides of 2-cyanopyrrolidine | NOVO NORDISK A/S (DK) | 2003-11-11 | — | — | US | disclosed |
| US-20030199528-A1 | Hetrocyclic compounds that are inhibitors of the enzyme DPP-IV | NOVO NORDISK A/S (DK) | 2003-10-23 | — | — | US | disclosed |
| US-20030186944-A1 | Such as 4-(2-(3-dimethylaminobenzoylamino)phenoxy)phthalic acid for treatment/prevention of diabetes; for inhibiting liver glycogen phosphorylase; dietetics | KRISTIANSEN MARIT (DK) | 2003-10-02 | — | — | US | disclosed |
| WO-2003078445-A2 | A BUILDING BLOCK FORMING A C=C DOUBLE BOND UPON REACTION | NUEVOLUTION A/S (DK) | 2003-09-25 | — | — | WO | disclosed |
| WO-2003078446-A2 | A BUILDING BLOCK FORMING A C-C OR A C-HETERO ATOM BOND UPON REACTION | NUEVOLUTION A/S (DK) | 2003-09-25 | — | — | WO | disclosed |
| WO-2003078050-A2 | A BUILDING BLOCK FORMING A C-C BOND UPON REACTION | NUEVOLUTION A/S (DK) | 2003-09-25 | — | — | WO | disclosed |
| WO-2003078627-A2 | A BUILDING BLOCK CAPABLE OF FUNCTIONAL ENTITY TRANSFER TO NUCLEOPHIL | NUEVOLUTION A/S (DK) | 2003-09-25 | — | — | WO | disclosed |
| WO-2003078626-A2 | A BUILDING BLOCK CAPABLE OF TRANSFERRING A FUNCTIONAL ENTITY | NUEVOLUTION A/S (DK) | 2003-09-25 | — | — | WO | disclosed |
| WO-2003076461-A2 | DIMERIC TF ANTAGONIST COMPRISING TWO FACTOR VII POLYPEPTIDES | NOVO NORDISK A/S (DK) | 2003-09-18 | — | — | WO | disclosed |
| US-20030171411-A1 | Amide derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2003-09-11 | — | — | US | disclosed |
| EP-1336607-A1 | Amide derivatives as glucokinase activators | NOVO NORDISK A/S (DK) | 2003-08-20 | — | — | EP | disclosed |
| WO-2003057200-A2 | COMPOSITIONS COMPRISING INHIBITORS OF DPP-IV AND NEP ENZYMES FOR THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2003-07-17 | — | — | WO | disclosed |
| WO-2003055482-A1 | AMIDE DERIVATIVES AS GK ACTIVATORS | NOVO NORDISK A/S (DK) | 2003-07-10 | — | — | WO | disclosed |
| US-6590118-B1 | Used in treatment of and/or prevention of diabetes, especially non-insulin dependent diabetes (Type 2 diabetes) | NOVO NORDISK A/S (DK) | 2003-07-08 | — | — | US | disclosed |
| US-20030105077-A1 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV | NOVO NORDISK A/S (DK) | 2003-06-05 | — | — | US | disclosed |
| EP-1301187-A2 | HETEROCYCLIC COMPOUNDS, WHICH ARE INHIBITORS OF THE ENZYME DPP-IV | NOVO NORDISK A/S (DK) | 2003-04-16 | — | — | EP | disclosed |
| US-20030069267-A1 | Modulators of protein tyrosine phosphatases (PTPases) | MOLLER NIELS PETER HUNDAHL (DK) | 2003-04-10 | — | — | US | disclosed |
| WO-2003024965-A2 | HETEROCYCLIC COMPOUNDS THAT ARE INHIBITORS OF THE ENZYME DPP-IV | NOVO NORDISK A/S (DK) | 2003-03-27 | — | — | WO | disclosed |
| US-6479505-B1 | TREATING AIRWAY DISORDER IN A PATIENT COMPRISING ADMINISTERING TO SAID PATIENT IN NEED THEREOF A THERAPEUTICALLY EFFECTIVE AMOUNT OF A PHOSPHODIESTERASE IV INHIBITOR | ALTANA PHARMA AG (DE) | 2002-11-12 | — | — | US | disclosed |
| US-20020165398-A1 | Modulators of protein tyrosine phosphatases (PTPases) | JEPPESEN LONE (DK) | 2002-11-07 | — | — | US | disclosed |
| EP-1254113-A1 | N-SUBSTITUTED 2-CYANOPYROLES AND -PYRROLINES WHICH ARE INHIBITORS OF THE ENZYME DPP-IV | NOVO NORDISK A/S (DK) | 2002-11-06 | — | — | EP | disclosed |
| US-20020161001-A1 | Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV | NOVO NORDISK A/S (DK) | 2002-10-31 | — | — | US | disclosed |
| US-6462046-B2 | NON-THIAZOLIDINEDIONE PPARGAMMA AGONISTS; USEFUL IN MODULATION OF BLOOD GLUCOSE AND THE INCREASE OF INSULIN SENSITIVITY IN MAMMALS | ADVANCED SYNTECH, LLC | 2002-10-08 | — | — | US | disclosed |
| US-20020103384-A1 | Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV | KANSTRUP ANDERS (DK) | 2002-08-01 | — | — | US | disclosed |
| EP-1220832-A1 | NOVEL AROMATIC COMPOUNDS | NOVO NORDISK A/S (DK) | 2002-07-10 | — | — | EP | disclosed |
| US-20020082263-A1 | Heterocycle derivatives as PPAR-gamma agonists | ADVANCED SYNTECH LLC | 2002-06-27 | — | — | US | disclosed |
| US-6410586-B1 | ANTICOAGULANTS; INSULIN RESISTANCE; ANTIALLERGENS | NOVO NORDISK A/S (DK) | 2002-06-25 | — | — | US | disclosed |
| US-6410556-B1 | ANTIDIABETIC AGENTS | NOVO NORDISK A/S (DK) | 2002-06-25 | — | — | US | disclosed |
| EP-1214324-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK A/S (DK) | 2002-06-19 | — | — | EP | disclosed |
| EP-1214325-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK A/S (DK) | 2002-06-19 | — | — | EP | disclosed |
| EP-1214060-A2 | METHOD OF INHIBITING PROTEIN TYROSINE PHOSPHATASE 1B AND/OR T-CELL PROTEIN TYROSINE PHOSPHATASE AND/OR OTHER PTPASES WITH AN ASP RESIDUE AT POSITION 48 | NOVO NORDISK A/S (DK) | 2002-06-19 | — | — | EP | disclosed |
| US-6380398-B2 | COMPOUNDS SUCH AS (S,S)1-(2-AMINO-3,3-DIMETHYL-BUTYRYL)-2,5-DIHYDRO-1H-PYRROLE-2 -CARBONITRILE ADMINISTERED AS ANTIDIABETIC AGENTS; DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | NOVO NORDISK A/S (DK) | 2002-04-30 | — | — | US | disclosed |
| US-20020019412-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK A/S (DK) | 2002-02-14 | — | — | US | disclosed |
| EP-1173438-A1 | SUBSTITUTED IMIDAZOLES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2002-01-23 | — | — | EP | disclosed |
| WO-2002002560-A2 | PURINE-2,6-DIONES WHICH ARE INHIBITORS OF THE ENZYME DIPEPTIDYL PEPTIDASE IV (DPP-IV) | NOVO NORDISK A/S (DK) | 2002-01-10 | — | — | WO | disclosed |
| US-20020002199-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK A/S (DK) | 2002-01-03 | — | — | US | disclosed |
| US-20010031780-A1 | New therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV | NOVO NORDISK A/S (DK) | 2001-10-18 | — | — | US | disclosed |
| US-6294539-B1 | METALLOCENE ENZYME INHIBITORS AS ANTICARCINOGENIC AGENTS, ANTITUMOR AGENTS AND ANTIARTHRITIC AGENTS | ADVANCED SYNTECH, LLC | 2001-09-25 | — | — | US | disclosed |
| WO-2001055105-A1 | N-SUBSTITUTED 2-CYANOPYROLES AND -PYRROLINES WHICH ARE INHIBITORS OF THE ENZYME DPP-IV | NOVO NORDISK A/S (DK) | 2001-08-02 | — | — | WO | disclosed |
| US-6262044-B1 | CONTAINING AN AMIDE-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE RING | NOVO NORDISK A/S (DK) | 2001-07-17 | — | — | US | disclosed |
| US-6235730-B1 | ANTICHOLESTEROL AGENT, ANTILIPEMIC AGENT | JAPAN TOBACCO, INC. (JP) | 2001-05-22 | — | — | US | disclosed |
| US-6225329-B1 | USEFUL IN THE TREATMENT OF TYPE I DIABETES, TYPE II DIABETES, IMPAIRED GLUCOSE TOLERANCE, INSULIN AUTOIMMUNITY DISEASES WITH DYSFUNCTIONS OF THE COAGULATION SYSTEM, ALLERGIC DISEASES | NOVO NORDISK A/S (DK) | 2001-05-01 | — | — | US | disclosed |
| WO-2001023347-A1 | NOVEL AROMATIC COMPOUNDS | NOVO NORDISK A/S (DK) | 2001-04-05 | — | — | WO | disclosed |
| WO-2001021661-A1 | BIVALENT INHIBITOR OF FVIIa/TF/FXa COMPLEX | NOVO NORDISK A/S (DK) | 2001-03-29 | — | — | WO | disclosed |
| WO-2001019831-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK A/S (DK) | 2001-03-22 | — | — | WO | disclosed |
| WO-2001019830-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK A/S (DK) | 2001-03-22 | — | — | WO | disclosed |
| WO-2001017516-A2 | METHOD OF INHIBITING PROTEIN TYROSINE PHOSPHATASE 1B AND/OR T-CELL PROTEIN TYROSINE PHOSPHATASE AND/OR OTHER PTPASES WITH AN ASP RESIDUE AT POSITION 48 | NOVO NORDISK A/S (DK) | 2001-03-15 | — | — | WO | disclosed |
| EP-1080095-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK A/S (DK) | 2001-03-07 | — | — | EP | disclosed |
| EP-1080068-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES | Novo Nordisk A/S (DK) | 2001-03-07 | — | — | EP | disclosed |
| US-6177443-B1 | ANTIDIABETIC AGENTS | NOVO NORDISK A/S (DK) | 2001-01-23 | — | — | US | disclosed |
| US-6169087-B1 | Modulators of protein tyrosine phosphatases (PTPases) | NOVO NORDISK A/S (DK) | 2001-01-02 | — | — | US | disclosed |
| EP-1062204-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK A/S (DK) | 2000-12-27 | — | — | EP | disclosed |
| EP-1062199-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK A/S (DK) | 2000-12-27 | — | — | EP | disclosed |
| US-6147051-A | ANTIISCHEMIC AGENT | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2000-11-14 | — | — | US | disclosed |
| WO-2000063208-A1 | SUBSTITUTED IMIDAZOLES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-10-26 | — | — | WO | disclosed |
| EP-0519353-B1 | Indolizin derivatives, process for their preparation and pharmaceutical composition containing them | FUJISAWA PHARMACEUTICAL CO (JP) | 2000-08-16 | — | — | EP | disclosed |
| EP-1019367-A1 | DERIVATIVES OF 2,5- AND 3,5-DISUBSTITUTED ANILINES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-07-19 | — | — | EP | disclosed |
| US-6090797-A | ADJUSTMENT OF GLUCOSE METABOLISM; HYPOGLYCEMIC AGENTS; ANTIDIABETIC AGENTS | NOVO NORDISK A/S (DK) | 2000-07-18 | — | — | US | disclosed |
| EP-1017697-A1 | MODULES OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK A/S (DK) | 2000-07-12 | — | — | EP | disclosed |
| US-6080770-A | SUBSTITUTED 1,2,3-TRIAZOLE OR 1,2,4-TRIAZOLE COMPOUND | NOVO NORDISK A/S (DK) | 2000-06-27 | — | — | US | disclosed |
| WO-2000030646-A1 | HETEROCYCLIC COMPOUNDS REGULATING CLOTTING | NOVO NORDISK A/S (DK) | 2000-06-02 | — | — | WO | disclosed |
| US-6063800-A | Modulators of molecules with phosphotyrosine recognition units | NOVO NORDISK A/S (DK) | 2000-05-16 | — | — | US | disclosed |
| EP-0680469-B1 | AMINOACID DERIVATES, MEDICAMENTS CONTAINING THESE COMPOUNDS AND PROCESS FOR PREPARING THE SAME | BOEHRINGER INGELHEIM PHARMA (DE) | 2000-04-26 | — | — | EP | disclosed |
| US-6043247-A | A SUBSTITUTED ACRYLIC ACIDS FOR USE IN TREATMENT OF HUMAN AND ANIMAL DISORDERS, AND PURIFICATION OF PROTEINS OR GLYCOPROTEINS, AND TO THEIR USE IN DIAGNOSIS | NOVO NORDISK A/S (DK) | 2000-03-28 | — | — | US | disclosed |
| WO-2000014090-A1 | 4,5,6,7-TETRAHYDRO-THIENO[2,3-C]PYRIDINE DERIVATIVES | NOVO NORDISK A/S (DK) | 2000-03-16 | — | — | WO | disclosed |
| EP-0973778-A1 | 4,5,6,7-TETRAHYDRO-THIENO 3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-01-26 | — | — | EP | disclosed |
| EP-0970954-A1 | 3-PIPERIDYL-4-OXOQUINAZOLINE DERIVATIVES AND MEDICINCAL COMPOSITIONS CONTAINING THE SAME | JAPAN TOBACCO INC. (JP) | 2000-01-12 | — | — | EP | disclosed |
| US-5972978-A | FOR USE IN TREATMENT OF HUMAN AND ANIMAL DISORDERS, USE FOR PURIFICATION OF PROTEINS OR GLYCOPROTEINS, USE IN DIAGNOSIS | NOVO NORDISK A/S (DK) | 1999-10-26 | — | — | US | disclosed |
| WO-1999046244-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK A/S (DK) | 1999-09-16 | — | — | WO | disclosed |
| WO-1999046267-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK A/S (DK) | 1999-09-16 | — | — | WO | disclosed |
| WO-1999046236-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK A/S (DK) | 1999-09-16 | — | — | WO | disclosed |
| WO-1999046237-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES | NOVO NORDISK A/S (DK) | 1999-09-16 | — | — | WO | disclosed |
| WO-1999045013-A1 | 4,5,6,7-TETRAHYDRO-THIENO[3,2-c]PYRIDINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1999-09-10 | — | — | WO | disclosed |
| WO-1999040062-A1 | HYDRAZONE DERIVATIVES | NOVO NORDISK A/S (DK) | 1999-08-12 | — | — | WO | disclosed |
| US-5925731-A | FOR TREATMENT OR PROPHYLAXIS OF ACUTE RENAL FAILURE, MYOCARDIAL INFARCTION, HEPATIC DISEASE, OR BRONCHIAL DISORDER | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-07-20 | — | — | US | disclosed |
| WO-1999015529-A1 | MODULES OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK A/S (DK) | 1999-04-01 | — | — | WO | disclosed |
| WO-1999007672-A1 | DERIVATIVES OF 2,5- AND 3,5-DISUBSTITUTED ANILINES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1999-02-18 | — | — | WO | disclosed |
| EP-0717742-B1 | PROCESS FOR THE PREPARATION OF INDOLIZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 1998-11-11 | — | — | EP | disclosed |
| WO-1998040385-A1 | 4,5,6,7-TETRAHYDRO-THIENO[3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1998-09-17 | — | — | WO | disclosed |
| EP-0852584-A1 | PEPTIDE DERIVATIVES HAVING ENDOTHELIN RECEPTOR ANTAGONISTIC ACTIVITY | Takeda Chemical Industries, Ltd. (JP) | 1998-07-15 | — | — | EP | disclosed |
| EP-0552489-B1 | Peptide, production and use thereof | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1998-03-04 | — | — | EP | disclosed |
| WO-1997039748-A1 | MODULATORS OF MOLECULES WITH PHOSPHOTYROSINE RECOGNITION UNITS | NOVO NORDISK A/S (DK) | 1997-10-30 | — | — | WO | disclosed |
| WO-1997040017-A2 | MODULATORS OF MOLECULES WITH PHOSPHOTYROSINE RECOGNITION UNITS | NOVO NORDISK A/S (DK) | 1997-10-30 | — | — | WO | disclosed |
| EP-0625507-B1 | Urea derivatives and their use as acat inhibitors | NISSHIN FLOUR MILLING CO (JP) | 1997-07-23 | — | — | EP | disclosed |
| US-5622953-A | DRUG RESISTANT TO ANTICANCER CHEMOTHERAPEUTIC DRUG | BASF AKTIENGESELLSCHAFT (DE) | 1997-04-22 | — | — | US | disclosed |
| US-5621010-A | ANTIHYPERCHOLESTEROLEMIA AND ANTIATHEROSCLEROSIS | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1997-04-15 | — | — | US | disclosed |
| WO-1997011961-A1 | PEPTIDE DERIVATIVES HAVING ENDOTHELIN RECEPTOR ANTAGONISTIC ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-04-03 | — | — | WO | disclosed |
| US-5616620-A | HYPOTENSIVE AGENTS | KARL THOMAE GMBH (DE) | 1997-04-01 | — | — | US | disclosed |
| EP-0458207-B1 | Indole derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-03-26 | — | — | EP | disclosed |
| US-5587383-A | CALMODULIN INHIBITORS; ANTIISCHEMIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-12-24 | — | — | US | disclosed |
| US-5405843-A | Anticancer drug potentiators | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1995-04-11 | — | — | US | disclosed |
| EP-0471236-B1 | Imidazopyridine derivatives and their use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1995-03-15 | — | — | EP | disclosed |
| US-5395839-A | Calmodulin and angiogenesis inhibitors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-03-07 | — | — | US | disclosed |
| EP-0363212-B1 | Novel heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components | MITSUI TOATSU CHEMICALS (JP) | 1995-01-04 | — | — | EP | disclosed |
| EP-0626174-A2 | Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-11-30 | — | — | EP | disclosed |
| EP-0625507-A2 | Urea derivatives and their use as acat inhibitors | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1994-11-23 | — | — | EP | disclosed |
| WO-1994022842-A1 | 1-AMINO-3-PHENOXY PROPANE DERIVATIVES AS MODULATORS OF MULTI-DRUG RESISTANCE | BASF AKTIENGESELLSCHAFT (DE) | 1994-10-13 | — | — | WO | disclosed |
| US-5334716-A | Preventing testosteron 5a-reductase mediated diseases; alopecia, acne, prostatism | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-08-02 | — | — | US | disclosed |
| US-5312829-A | Testosterone 5alpha-reductase inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-05-17 | — | — | US | disclosed |
| US-5244908-A | Calmodulin inhibitors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-09-14 | — | — | US | disclosed |
| EP-0552489-A2 | Peptide, production and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-07-28 | — | — | EP | disclosed |
| US-5212320-A | Enzyme inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-05-18 | — | — | US | disclosed |
| US-5204348-A | Quinoline derivatives | MITSUI TOATSU CHEMICALS INC. (JP) | 1993-04-20 | — | — | US | disclosed |
| EP-0301751-B1 | PYRIDINIUM DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1993-03-10 | — | — | EP | disclosed |
| WO-1993003012-A1 | INDOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-02-18 | — | — | WO | disclosed |
| EP-0519353-A2 | Indolizin derivatives, process for their preparation and pharmaceutical composition containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-12-23 | — | — | EP | disclosed |
| US-5112817-A | Anticancer Drug Potentiators | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1992-05-12 | — | — | US | disclosed |
| EP-0471236-A1 | Imidazopyridine derivatives and their use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-02-19 | — | — | EP | disclosed |
| EP-0458207-A2 | Indole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-11-27 | — | — | EP | disclosed |
| US-4962113-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD (JP) | 1990-10-09 | — | — | US | disclosed |
| EP-0369810-A2 | PAF antagonists as anti-hyperendothelinemia agents | Takeda Chemical Industries, Ltd. (JP) | 1990-05-23 | — | — | EP | disclosed |
| EP-0363212-A2 | Novel heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1990-04-11 | — | — | EP | disclosed |
| EP-0301751-A1 | Pyridinium derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1989-02-01 | — | — | EP | disclosed |
| EP-0301751-A1 | Pyridinium derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1989-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022558-A1 | PHEBOX LIGANDS AND METHODS OF MAKING SAME | ALKBH3, DDC, PAH | NOS3 1684/4885NOS1 2748/4885NOS2 2096/4885 |
| US-20230271994-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | ASGR1, MSR1, LDLR | NOS3 3245/4885NOS1 2351/4885NOS2 2990/4885 |
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | NOS3 2135/4885NOS1 1399/4885NOS2 3046/4885 |
| US-20080139562-A1 | Heteroaromatic Glucokinase Activators | GCK, GCKR, PDXK | NOS3 2795/4885NOS1 3771/4885NOS2 2669/4885 |
| US-20170252350-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | XBP1, ERN1, ERN2 | NOS3 4315/4885NOS1 4025/4885NOS2 4408/4885 |
| US-20160200703-A1 | NOVEL AND SPECIFIC INHIBITORS OF CYTOCHROME P450 26 RETINOIC ACID HYDROXYLASE | CYP2B6, CYP26A1, CYP2A6 | NOS3 774/4885NOS1 1014/4885NOS2 982/4885 |
| US-20230265099-A1 | SIK INHIBITORS AND METHODS OF USE THEREOF | SIK2, SIK1, SIK3 | NOS3 3516/4885NOS1 3656/4885NOS2 3446/4885 |
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | ITGB1, ITGB2, ITGA2 | NOS3 4128/4885NOS1 3087/4885NOS2 3322/4885 |
| US-20040034014-A1 | Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV | DPP4, DPP7, DPP3 | NOS3 2518/4885NOS1 3293/4885NOS2 2522/4885 |
| US-20060276410-A1 | COMPOUNDS AND METHODS FOR SELECTIVE INHIBITION OF DIPEPTIDYL PEPTIDASE-IV | DPP4, DPP3, DPP7 | NOS3 1534/4885NOS1 2612/4885NOS2 2842/4885 |
| US-20050054618-A1 | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases | PYGM, GYS1, AGL | NOS3 342/4885NOS1 674/4885NOS2 638/4885 |
| US-11891399-B2 | Inhibitors of cancer invasion, attachment, and/or metastasis | SDCBP, SDC1, SDAD1 | NOS3 4802/4885NOS1 4764/4885NOS2 4869/4885 |
| US-20150210673-A1 | NOVEL KAPPA OPIOID LIGANDS | OPRK1, OPRD1, OPRL1 | NOS3 2584/4885NOS1 3308/4885NOS2 2990/4885 |
| US-20230322741-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | ACKR3, CCR5, CXCR3 | NOS3 2694/4885NOS1 3325/4885NOS2 2708/4885 |
| US-11697736-B2 | Silicon containing detectable compounds | AS3MT, SCLY, NASP | NOS3 1046/4885NOS1 1634/4885NOS2 1208/4885 |
| US-20240041768-A1 | MULTIFUNCTIONAL pO2/pH-SENSITIVE THERANOSTIC LIPOSOME NANOCARRIERS AND METHODS OF USING SAME | HIF1A, HIF1AN, EGLN2 | NOS3 581/4885NOS1 642/4885NOS2 321/4885 |
| US-20140364433-A1 | SUBSTITUTED PROLINES / PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OPRL1 | NOS3 2767/4885NOS1 1600/4885NOS2 1320/4885 |
| US-20210371409-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, GCGR | NOS3 3390/4885NOS1 2463/4885NOS2 4012/4885 |
| US-20170258795-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | PSMG3, PSME1, PSMB1 | NOS3 4745/4885NOS1 4827/4885NOS2 4843/4885 |
| US-20130196966-A1 | SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | S1PR1, S1PR3, S1PR2 | NOS3 4198/4885NOS1 3668/4885NOS2 4477/4885 |
| US-20060018831-A1 | TF binding agent and use thereof | TFPI, F3, TFPI2 | NOS3 4494/4885NOS1 4471/4885NOS2 4374/4885 |
| US-20150166605-A1 | LINEAR PEPTIDE ANTIBIOTICS | SPAST, PEPD, NPEPPS | NOS3 3772/4885NOS1 3388/4885NOS2 4017/4885 |
| US-10174005-B2 | Fused pyrimidines as inhibitors of p97 complex | WDR77, POP1, PSMG3 | NOS3 4758/4885NOS1 4846/4885NOS2 4831/4885 |
| US-20210214365-A1 | INHIBITORS OF CANCER INVASION, ATTACHMENT, AND/OR METASTASIS | SDCBP, SDC1, SDAD1 | NOS3 4802/4885NOS1 4764/4885NOS2 4869/4885 |
| US-20020165398-A1 | Modulators of protein tyrosine phosphatases (PTPases) | PTPRCAP, PTPRS, PTPRO | NOS3 3943/4885NOS1 2961/4885NOS2 3285/4885 |
| US-10787437-B2 | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-HT2A serotonin receptor | HTR5A, HTR2A, HTR3A | NOS3 572/4885NOS1 864/4885NOS2 469/4885 |
| US-20230150956-A1 | MYC INHIBITORS AND USES THEREOF | MYC, AURKA, AURKC | NOS3 3822/4885NOS1 3534/4885NOS2 3632/4885 |
| US-20130018040-A1 | Compositions And Methods For Treating Toxoplasmosis, Cryptosporidiosis, And Other Apicomplexan Protozoan Related Diseases | PNCK, TXK, CILK1 | NOS3 2517/4885NOS1 3267/4885NOS2 2955/4885 |
| US-20070060547-A1 | (2R)-1-{2-[(3R)-pyrrolidin-3-ylamino]-acetyl}-pyrrolidine-2-boronic acid; Dipeptidyl peptidase IV (DPP-IV) inhibitors; diabetes, hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis | DPP4, DPP7, DPP3 | NOS3 2160/4885NOS1 2949/4885NOS2 2570/4885 |
| US-20220411396-A1 | TRIOXOLANE AGENTS | ABCB4, SLC10A1, SLC10A2 | NOS3 3493/4885NOS1 3282/4885NOS2 3194/4885 |
| US-20110046121-A1 | INHIBITORS OF FOCAL ADHESION KINASE | PTK2, CABLES1, TNK2 | NOS3 3913/4885NOS1 3975/4885NOS2 4161/4885 |
| US-20240158355-A1 | BET SUBFAMILY INHIBITORS AND METHODS USING SAME | BRDT, BRD3, BRD2 | NOS3 4337/4885NOS1 4516/4885NOS2 4462/4885 |
| US-20150045372-A1 | PROCESSES FOR THE PREPARATION OF PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR | HTR5A, HTR2A, HTR3A | NOS3 572/4885NOS1 864/4885NOS2 469/4885 |
| US-20200338541-A1 | CATALYST AND METHOD FOR FRACTIONATING LIGNOCELLULOSIC MATERIAL | MGAM, ALDOA, ME1 | NOS3 2209/4885NOS1 2115/4885NOS2 2014/4885 |
| US-20220002231-A1 | PARG INHIBITORS AND METHOD OF USE THEREOF | PARG, PARP12, PARP15 | NOS3 3265/4885NOS1 3353/4885NOS2 2874/4885 |
| US-20070213519-A1 | Building Block Forming A C=C Double Bond Upon Reaction | TBCB, COASY, RTCB | NOS3 4313/4885NOS1 4295/4885NOS2 4188/4885 |
| US-11191745-B2 | Silica nanoparticle with an insoluble drug | TSG101, TP53, ABCC1 | NOS3 307/4885NOS1 442/4885NOS2 410/4885 |
| US-11970735-B2 | Nucleotide cleavable linkers and uses thereof | NUDT21, CPSF7, DCLRE1A | NOS3 3741/4885NOS1 3883/4885NOS2 4003/4885 |
| US-20230108783-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | UTRN, POLRMT, SMN1; SMN2 | NOS3 3528/4885NOS1 3867/4885NOS2 4342/4885 |
| US-20230052740-A1 | MODULATORS OF CIRCADIAN RHYTHMS AND USES THEREOF | MTNR1A, PER2, MTNR1B | NOS3 2576/4885NOS1 3056/4885NOS2 2185/4885 |
| US-20230365542-A1 | Selective Agonists of 5-HT2A Receptor and Methods of Use | HTR2A, HTR2C, HTR2B | NOS3 2311/4885NOS1 2369/4885NOS2 1248/4885 |
| US-20180273537-A1 | COMPOSITIONS AND METHODS FOR TREATING TOXOPLASMOSIS, CRYPTOSPORIDIOSIS AND OTHER APICOMPLEXAN PROTOZOAN RELATED DISEASES | PNCK, TXK, CAMKK1 | NOS3 2081/4885NOS1 2951/4885NOS2 2813/4885 |
| US-20110053958-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, TBXA2R | NOS3 848/4885NOS1 594/4885NOS2 302/4885 |
| US-20200316010-A1 | SILICA NANOPARTICLE WITH AN INSOLUBLE DRUG | TSG101, TP53, ABCC1 | NOS3 307/4885NOS1 442/4885NOS2 410/4885 |
| US-10544136-B2 | Modulators of sphingosine phosphate receptors | S1PR1, S1PR3, S1PR2 | NOS3 4164/4885NOS1 3930/4885NOS2 4571/4885 |
| US-20210171455-A1 | ALPHA-5 BETA-1 INHIBITORS | SCN5A, PSMA5, API5 | NOS3 2474/4885NOS1 778/4885NOS2 2829/4885 |
| US-20130217706-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PTGER2 | NOS3 242/4885NOS1 284/4885NOS2 75/4885 |
| US-20030069267-A1 | Modulators of protein tyrosine phosphatases (PTPases) | PTPRCAP, PTPRS, PTPRA | NOS3 3959/4885NOS1 2988/4885NOS2 3293/4885 |
| US-20020082263-A1 | Heterocycle derivatives as PPAR-gamma agonists | PPARG, PPARD, PPARA | NOS3 2236/4885NOS1 2448/4885NOS2 2459/4885 |
| US-20190084947-A1 | NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS | S1PR1, S1PR3, S1PR2 | NOS3 3945/4885NOS1 3743/4885NOS2 4521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.